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 Amyotrophic Lateral Sclerosis (ALS) is an adult-onset progressive 
neurodegenerative disease characterized by the selective loss of motor neuron 
function leading to muscle atrophy and weakness. After symptoms onset 
patients last 4 to 5 years and ultimately die due to bulbar failure.  
 Animal models have been developed to study the neurobiology of ALS, 
with the SOD1G93A mouse model as the most studied so far. Morphological 
and functional abnormalities have been reported in both pre-symptomatic and 
symptomatic stages of ALS progression in this rodent model. Dysfunctions in 
neuromuscular transmission at phrenic nerve-hemidiaphragm preparations of 
the SOD1G93A mouse have recently been put in evidence by our group. Since 
adenosine A2A receptors (A2AR) play a major role in fine-tuning 
neurotransmitter release in mammalian neuromuscular junctions (NMJs), we 
decided to evaluate how A2AR modulate acetylcholine (ACh) release in pre-
symptomatic (4-6 weeks old (wo)) and symptomatic (12-14 wo) SOD1G93A 
mice. 
 Using the selective A2AR agonist CGS 21680, we performed a dose-
response study using 3, 5 and 10 nM in pre-symptomatic SOD1G93A mice and 
age-matched Wild Type (WT) animals. CGS 21680 at 3, 5, 10 and 25 nM was 
studied in symptomatic SOD1G93A and 12-14 wo WT rodents. 25 nM was used 
in the previous mentioned group of animals to verify if at concentrations higher 
than 10nM CGS 21680 effect in NMT would be increased. Intracellular 
recordings of endplate potentials (EPPs), miniature endplate potentials 
(MEPPs) and giant miniature endplate potentials (GMEPPs) where performed in 
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high [Mg2+] paralyzed phrenic nerve-hemidiaphragm preparations. Low-
frequency stimuli (0.5 Hz) allowed the evaluation of the evoked activity (EPPs) 
while spontaneous activity (MEPPs and GMEPPs) was measured in gap-free 
intervals. Quantal content (QC) was measured as the ratio between the mean 
EPP amplitude and the mean MEPP amplitude recorded in the same period of 
time.  
 We first validated high [Mg2+] as an useful method to study 
neuromuscular transmission (NMT) in these mice. The shift in the Ca2+/Mg2+ 
ratio preserved the previous described features of ACh release in SOD1G93A 
mice diaphragm fibers.  
 In the pre-symptomatic phase, SOD1G93A mice displayed a significant 
increase in EPP amplitude and QC in tested concentrations of CGS 21680 
when compared to WT mice (p<0.05 Unpaired t-test) except for EPP changes 
at 3nM (p>0.05 Unpaired t-test). MEPP and GMEPP amplitude were not 
changed by CGS 21680 (p>0.05 Paired t-test). The A2AR-mediated increase in 
MEPP frequency was not statistically different between both groups in the 
presence of 3 and 10nM of the A2AR agonist (p>0.05 Unpaired t-test), but was 
significantly higher in SOD1G93A mice when perfused at 5nM (p<0.05 
Unpaired t-test). We also found that in the pre-symptomatic SOD1G93A fibers 
GMEPP frequency was statistically higher in the presence of CGS 21680 (5nM) 
than in age-matched WT NMJs (p<0.05 Unpaired t-test). 
 In the symptomatic phase, CGS 21680 did not elicit any changes in 
SOD1G93A mice evoked (EPP amplitude and QC) and spontaneous (MEPP 
and GMEPP frequency and amplitude) activity from SOD1G93A mice (p>0.05 
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Paired t-test). When 0.5 Hz stimuli were delivered, EPP amplitude, QC and 
MEPP frequency were increased in 12-14 wo WT mice in the presence of 3, 5, 
10 and 25 nM of CGS 21680 (p<0.05 Paired t-test). These parameters together 
with GMEPP frequency were significantly higher than in symptomatic mice 
(p<0.05 Unpaired t-test). GMEPP and MEPP amplitude were not changed by 
CGS 21680 in older WT mice (p>0.05 Paired t-test). 
 The A2AR receptor antagonist SCH 58261 (50nM) was devoid of effect 
in spontaneous and evoked release (p>0.05 Paired t-test) and effectively 
blocked CGS 21680 (5nM in 4-6 wo mice and 10 nM in 12-14 wo WT rodents) 
facilitation (p<0.05 one-way ANOVA followed by Tukey’s pos-hoc). 
 Our results strongly suggest an early functionally enhancement of NMT 
concerning adenosine modulation before symptoms appear. This dysfunction 
involves an A2AR functional upregulation at diaphragm NMJs in pre-
symptomatic SOD1G93A mice. 
 When symptoms start to develop, A2AR receptor function is lost in 
symptomatic SOD1G93A mice but remains present in 12-14 wo WT mice. 
Furthermore, CGS 21680 perfusion triggered a higher A2AR facilitation in 12-14 
wo than in 4-6 wo WT mice. This might be attributable to a normal maturation 
feature of the studied synapse, which contrasted with the observations in 
transgenic mice. 
 The shift from a functional upregulation of A2AR before symptomatology 
that arises in SOD1G93A mice towards an apparent loss of A2AR functionality 
in symptomatic phase, highlights the role of this subtype of P1 receptors in the 
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scope of ALS. A2AR targeted drugs could eventually play an import role in the 





 A Esclerose Lateral Amiotrófica (ALS) é uma doença neurodegenerativa 
progressiva caracterizada pela perda seletiva da função do neurónio motor, 
levando a atrofia e fraqueza muscular. Após o início dos sintomas a esperança 
de vida dos doentes é de cerca de 4 a 5 anos, sendo a causa da morte 
geralmente devida a insuficiência respiratória. 
 Modelos animais têm sido desenvolvidos para estudar a neurobiologia 
da ALS, sendo o do murganho SOD1G93A o mais estudado. Neste modelo, 
anormalidades morfológicas e funcionais têm sido relatadas em ambos os 
estadios pré-sintomático e sintomático da ALS. Disfunções na transmissão 
neuromuscular (NMT) em preparações de nervo frénico-hemidiafragma de 
murganho SOD1G93A foram recentemente postas em evidência pelo nosso 
grupo. Considerando que os recetores A2A de adenosina (A2AR) 
desempenham um papel importante no controlo da libertação de acetilcolina 
(ACh) na junção neuromuscular (NMJ) de mamífero, explorámos o papel dos 
A2AR na modulação da NMT em murganhos SOD1G93A nas fases pré-
sintomática (4-6 semanas de idade) e sintomática (12-14 semanas de idade).  
 Usando o agonista seletivo dos A2AR (CGS 21680), foi realizado um 
estudo de dose-resposta utilizando concentrações de 3, 5 e 10 nM em animais 
pré-sintomáticos SOD1G93A e Wild Type (WT) (4-6 semanas). CGS 21680 a 3, 
5, 10 e 25 nM foi utilizado em murganhos sintomáticos SOD1G93A e WT (12 - 
14 semanas). A concentração 25 nM foi testada neste último grupo, de modo a 
verificar se a concentrações superiores a 10 nM o efeito modulador do CGS 
21680 na NMT estaria aumentado. Foram realizados registos intracelulares de 
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potenciais de placa motora (EPPs), potenciais miniatura de placa motora 
(MEPPs) e potenciais miniatura gigantes de placa motora (GMEPPs) em 
preparações de nervo frénico-hemidiafragma paralisadas com elevada [Mg2+]. 
Estímulos de baixa frequência (0.5 Hz) permitiram a avaliação da atividade 
evocada (EPPs), ao passo que as atividades espontâneas (MEPPs e GMEPPs) 
foram medidas sem estimulação elétrica. O conteúdo quântico (QC) foi 
considerado como sendo a razão entre a média da amplitude dos EPPs e 
média da amplitude dos MEPPs registados no mesmo período de tempo. 
 Inicialmente validámos o aumento da [Mg2+] como um método útil para o 
estudo da NMT nos murganhos SOD1G93A. A alteração do equilíbrio entre a 
razão Ca2 +/ Mg2+ preservou as características da NMT anteriormente descritas 
neste modelo. 
 Na fase pré-sintomática, os animais SOD1G93A apresentaram um 
aumento na amplitude do EPP e do QC nas concentrações testadas de CGS 
21680 quando comparado com murganhos WT (p<0.05 Unpaired t-test), exceto 
nas variações do EPP a 3nM (p>0.05 Unpaired t-test). A amplitude dos MEPPs 
e GMEPPs não foram alteradas pelo CGS 21680 (p>0.05 Paired t-test). O 
aumento na frequência dos MEPPs resultante da ativação dos A2AR não foi 
significativamente diferente entre os dois grupos na presença de 3 e 10 nM do 
agonista dos A2AR (p>0.05 Unpaired t-test) mas foi estatisticamente superior 
em murganhos SOD1G93A quando perfundido a 5nM (p<0.05 Unpaired t-test). 
As NMJs dos animais SOD1G93A pré-sintomáticos apresentaram aumento na 
frequência dos GMEPPs na presença de CGS 21680 (5 nM) quando 
comparadas com as dos animais WT (p<0.05 Unpaired t-test). 
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 Na fase sintomática, o CGS 21680 não alterou a resposta evocada 
(amplitude dos EPP e QC) nem a atividade espontânea (frequência e amplitude 
dos MEPPs e GMEPPs) dos animais SOD1G93A (p>0.05 Paired t-test). Após 
estimulação de 0.5 Hz a amplitude dos EPPs, QC e frequência dos MEPPs 
aumentaram em murganhos WT na presença de 3, 5, 10 e 25 nM de CGS 
21680 (p<0.05 Paired t-test). Estes parâmetros, juntamente com frequência dos 
GMEPPs foram significativamente mais elevados do que em murganhos 
sintomáticos (p<0,05 Unpaired t-test). A amplitude dos GMEPPs e MEPPs não 
foram alteradas pela aplicação de CGS 21680 em murganhos WT (p>0.05 
Paired t-test). 
 O antagonista dos A2AR SCH 58261 (50nM) não alterou a actividade 
espontânea e evocada (p>0.05 Paired t-test) mas bloqueou eficazmente o 
efeito facilitatório do CGS 21680 (a 5nM em animais de 4-6 semanas e a 10nM 
em murganhos WT com 12-14 semanas) (p<0.05 Unpaired t-test). 
 Os resultados deste estudo apontam para a existência de uma disfunção 
da modulação adenosinérgica na libertação de ACh  antes do aparecimento 
dos sintomas. Esta disfunção envolve uma sobrerregulação funcional dos 
A2AR nas NMJs de diafragma de murganhos SOD1G93A pré-sintomáticos. 
 Quando os sintomas começam a aparecer, a função dos A2AR parece 
desaparecer em murganhos sintomáticos, mas permanece presente em 
animais WT de 12-14 semanas de idade. Além disso, o CGS 21680 promoveu 
uma facilitação A2AR superior em murganhos WT de 12-14 semanas do que 
de 4-6 semanas. Isto pode ser atribuído a uma característica normal de 
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maturação da sinapse, contrastando com as observações em animais 
SOD1G93A. 
 A passagem de uma sobrerregulação funcional dos A2AR antes da 
sintomatologia surgir para uma aparente perda da funcionalidade dos A2AR 
durante a fase sintomática em animais  SOD1G93A, destaca o papel deste 
subtipo de recetores P1 no âmbito da ALS. Tendo isto em consideração, 
fármacos que atuem nos A2AR poderão eventualmente desempenhar um 
















A1R - A1 adenosine receptor 
A2AR -  A2A adenosine receptor 
ACh - acetylcholine 
AChE - acetylcholinesterase 
ALS - Amyotrophic Lateral Sclerosis 
ANOVA - analysis of variance 
AP - action potential 
ATP - adenosine-5'-triphosphate 
cAMP - cyclic adenosine-5'-monophosphate 
CGS 21680 - 2-p-(2-carboxyethyl) phenethylamino]-5’-N-ethylcarboxamido 
adenosinehydrochloride 
DAG - diacyl glycerol 
EMG - electromyography 
ER - endoplasmic reticulum 
FALS - familial form of Amyotrophic Lateral Sclerosis 
FTD - frontotemporal degeneration 
FUS - DNA/RNA binding protein fused in sarcoma 
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GMEPP - giant miniature endplate potential 
IgG - immunoglobulin G 
IP3 - inositol 1,4,5-trisphosphate 
MEPP - miniature endplate potential 
MN - motor neuron 
MRI - magnetic resonance imaging 
nAChR - nicotinic acetylcholine receptor 
NMJ - neuromuscular junction 
NMT - neuromuscular transmission 
PCR - polimerase chain reaction 
PKA - protein kinase A 
PKC - protein kinase C 
PLC - phospholipase C 
QC - quantal content 
SALS - sporadic form of Amyotrophic Lateral Sclerosis 
SCH 58261 - 5-Amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo(4,3-e)-1,2,4-
triazolo(1,5-c) pyrimidine 
SOD1 - superoxide dismutase 1 
18 
 
SOD1G93A - glycine93→alanine point-mutation in human SOD1 protein 
TDP-43 - TAR-DNA binding protein 43 
VGCC - voltage-gated calcium channel 


















1.1. Amyotrophic Lateral Sclerosis 
1.1.1. Definition of the disease 
 Amyotrophic Lateral Sclerosis (ALS) was first described by Charles Bell 
in 1824. In 1869 the French doctor Jean Marie Charcot established the first 
pathophysiologic medical definition of the disease. He linked abnormal limb 
movement to the corticospinal tract pathology and motor neuron (MN) number 
loss to lower motor degeneration. He then named the disease as ALS 
incorporating the aspects of gray matter lesion (amyotrophic) and white matter 
damage (lateral sclerosis) in the spinal cord [1]. Charcot was well aware of the 
disease fast progression and inability to interfere with its development, a feature 
that still prevails to this day being ALS one of the major and lethal 
neurodegenerative diseases. 
 Despite variable etiology, ALS is considered as a single entity due to a 
specific recognizable clinical pattern. It is defined as a progressive 
neurodegenerative disease affecting neuronal cells, in particular MNs. Both 
upper and lower MNs degenerate leading to progressive denervation of muscle 
fibers. This results in impairment of neuromuscular transmission (NMT) with 
subsequent muscle weakness and volume loss. Patients present motor 
abnormalities with the majority displaying limb weakness as the first sign. ALS 
evolution will ultimately result in paralysis and patients usually die due to bulbar 
failure (see [2-3]).   
 The onset of ALS defines the clinical phenotype, differences in disease 
severity and life expectancy. Bulbar or spinal dysfunction are considered the 
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main triggers for ALS associated with a median survival between 3 to 4 years. 
Bulbar onset represents 25-30% of the cases and is denounced by dysphagia 
or dysarthria with the last being a strong predictive of impaired locomotion [4]. It 
is considered the onset with the worst prognosis and usually leads to an earlier 
respiratory involvement [5]. Limb symptoms (70-75% of all cases) point to a 
spinal onset that is usually associated with a better prognostic. In 5% of cases 
patients exhibit a respiratory involvement (see [2-3, 6]). 
 Prognostic heterogeneity is present in both bulbar and spinal forms of 
ALS [4]. Sometimes patients can last up to 10 years and exhibit a less severe 
phenotype. Along with the lack of a specific biomarker, the clinical heterogeneity 
in ALS remains a challenge and the often used bulbar or spinal distinction may 
not be adequate. Therefore early diagnosis remains an important feature for 
prognosis. Due to the overlap with related phenotypes, only well trained 
clinicians may accurately identify ALS as the cause of MN dysfunction 
symptoms (see [3, 6]).  
1.1.2. Clinical diagnosis  
 Diagnosis is established by excluding other possible causes of MN 
disease such as primary lateral sclerosis, progressive muscle atrophy or 
progressive bulbar palsy. Definite ALS involves both upper and lower MN 
degeneration and progression of this condition. The diagnostic criteria (El 
Escorial and Airlie House criteria and the more sensitive Awaji Criteria) are 
important guidelines and combine several clinical observations in ALS patients 
towards a correct diagnosis (see [3, 7]).  
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 Tests to rule out the other conditions and confirm ALS include 
electromyography (EMG), nerve conduction velocity and magnetic resonance 
imaging (MRI). Blood and urine samples can be used to eliminate the possibility 
of other diseases (see[3, 7]).  
 Fasciculations are synonymous of widespread disturbance in membrane 
excitability and MN degeneration. They are hallmark abnormalities in ALS 
commonly identified by EMG [8-9]. Motor unit number estimation is also an 
assessable parameter by EMG that increases certainty in diagnosis ([10] but 
see [11]). Transmagnetic stimulation may help to unveil upper MN dysfunction. 
MRI is a neuroimagiological non-invasive technique useful to exclude ALS-like 
syndromes [3, 7]. Only a combination of these techniques along with monitoring 
the progress of the disease can account for certainty in clinical diagnosis. With 
the lack of a specific biomarker the diagnosis is almost exclusively remitted to a 
symptomatic stage ([12] see [3, 7]). 
1.1.3. Epidemiology 
New cases are reported every year between 1.5 and 2.5 per 100 000 
individuals. 5 to 10% of these cases represent an inherited form of the disease 
designated familial ALS (FALS) while the other percentage encompasses a 
sporadic onset (SALS). In SALS, affected individuals start displaying symptoms 
from 55 to 65 years, while FALS onset starts a decade earlier (see [13]). Some 
of SALS cases derive from misdiagnosis, poorly ascertained family history and 
denial thus not reflecting the statistical reality [14]. Mutations arise in several 
key proteins resulting in disruption of cellular homeostasis capable of triggering 
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the ALS-phenotype. There are 104 genes with mutations related to the 
occurrence of ALS [15].  
In order to study the biological mechanisms inherent to the disease, 
transgenic animals have been developed. Mutations from the FALS form of the 
disease are the basics for the development of these genetic models (see [16]).  
1.2. Animal Models of ALS 
Mutations of the superoxide dismutase 1 (SOD1) were among the first 
discovered in FALS patients and the first integrated in a mouse model [17] 
which became the most studied transgenic rodent model of ALS so far. 
However, since mutations in the SOD1 gene represented only 20% of FALS 
and with the discovery of novel genes related with ALS, other models were also 
developed (see figure 1.3.1). The TAR-DNA binding protein 43 (TDP-43) is a 
nuclear protein important in gene regulation. It is found co-localized with 
ubiquitinated inclusions in both SALS and FALS forms and often associated 
with the Frontotemporal Dementia (FTD) / ALS complex [18-19]. The DNA/RNA 
binding protein fused in sarcoma (FUS) is a regulator of transcription. Mutations 
in this protein can lead to ALS in a similar proportion as TDP-43 dysfunction. 
SOD1, TDP-43 and FUS are considered the most widely accepted ALS-causing 
genes and therefore the most studied and developed rodent models of the 
disease (see [20] and [16], [21]). 
Recently, the C9orf72 gene expansion was found causative of ALS and 
FTD. This breakthrough in the understanding of ALS etiology highlighted a 
pleiotropy eventually responsible of triggering different phenotypes (see [22]). 
The number of repetitions of the C9orf72 expansion can account for the severity 
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and complexity of the disease [21] and may represent a significant percentage 
of SALS cases [23]. A zebrafish model of ALS has recently putted in evidence 
the MN deficits behind the aberrant C9orf92 expansion [24]. 
Other genes encoding proteins such as valosine-containing protein, 
profilin-1 and other proteins have also been related with the occurrence of ALS. 
This led to the development of new animal models in order to understand the 
biochemical mechanisms behind this disease in a more broader perspective 
(see [16]).  
1.3. The SOD1G93A mouse as a model to understand ALS 
 The SOD1 is an ubiquitous enzyme responsible for the catalyzation of 
reactive oxygen species into hydrogen peroxide in order to prevent oxidative 
damage events (e.g. lipid peroxidation, DNA damage and apoptosis). There are 
several mutations in the SOD1 gene that can trigger the ALS-phenotype. The 
shift in the residue 93 from a glycine into an alanine (SOD1G93A), allows a 
toxic gain-of-function that gives rise to MN degeneration (see [16, 25]).  Since 
Gurney et al (1994) first developed the SOD1G93A mouse it became the most 
studied model of the disease. One of the major advantages of using this model, 
is that it highlights developmental pathological features of the neuronal 
dysfunction (see [26]). This point-mutation in the SOD1 enzyme triggers an 
intrinsic progression in disease symptomatology in mice, that resembles the 
clinical variability of ALS .The majority of the findings related to unveiling the 
cellular dysfunctions as well as the therapeutics trialed in rodent models of ALS 
were tested in the G93A mutation of the SOD1 gene (see [16]). 
 In ALS two major stages of disease progression can be distinguished: 
pre-symptomatic and symptomatic phase. The clear understanding of these 
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stages in both animal models and humans may reveal fruitful insights of the 
ALS multifactorial etiology (see [27]) (see table 1.3.I). 
 
1.3.1. Pre-symptomatic ALS: insights from the SOD1G93A mouse 
 In this rodent model of ALS, symptoms start to arise approximately at 10 
weeks of age [17, 28]. Hyperexcitability is a phenomenon that starts long before 
symptomatology emerges. It can be functionally observed in SOD1G93A motor 
cortex, spinal cord [29-30] and neuromuscular junction [31]. Cortical 
hyperexcitability is detectable in pre-symptomatic patients [32] and may 
contribute to anterior horn excitotoxic cell degeneration (see[33]). An increase in 
persistent voltage gated sodium channel currents in pre-symptomatic ALS can 
relate to an endophenotype susceptible to the occurrence of fasciculations in 
humans and leading to MN excitotoxic death [34]. Reduced inhibitory tonus by 
alterations in Renshaw cells [35], CB1 receptor trafficking [36] and astrocytic 
mediators [37] also contributes to hyperexcitability. Indeed, this phenomenon is 
a strong predictor of survival [38] and may precede ALS onset in patients [39]. 
 Morphologically, SOD1G93A mice start to display MN retraction before 
symptoms arise with large caliber fibers being the most susceptible [40-41]. 
Bioenergetic alterations related with mitochrondrial dysfunction may contribute 
to future functional impairments [42]. Shifting in cellular signaling and gene 
expression also occurs [43-44]. 
 Studying pre-symptomatic ALS may help to uncover disease-induced 
maladaptations to ward off symptoms, contributing to the understanding of the 




1.3.2. Symptomatic ALS: insights from the SOD1G93A mouse 
 The symptomatic phase is characterized by a selective dysfunction and 
degeneration of MNs. Axonal transport impairment, activation of microglia, 
production of toxic factors by glial cells, Ca2+ dysfunction and glutamate 
excitotoxicity are hallmarks of this phase (see[25]). In the motor cortex of ALS 
patients there is evidence of disconnection along brain networks [45] together 
with progressive hypometabolism [46]. White and grey matter volume decrease 
occurs at brain areas of ALS patients (see[47]) which is correlated with 
observations of global atrophy in the brain and cerebellum of SOD1G93A mice 
[48]. Impaired oligodendrocyte regeneration in the spinal cord and motor cortex 
is evident in SOD1G93A mice [49]. Metabolic failures become more severe [50] 
and accountable for increased energy needs in ALS patients [51]. 
 MN retraction leads to an increment of skeletal muscle fiber atrophy [41] 
which justifies impairments in NMT  and muscle strength loss at this stage [31, 
40, 52].  
 In symptomatic ALS, multifactorial cellular dysfunction is enhanced 
contributing to the progression of neurodegeneration. This parallels with the 
evolution of symptoms and results in impairment of motor performance.  
 Despite some valid criticism (see [2]), the resemblance between 
SOD1G93A mice characteristics and clinical features of ALS progression  





Figure 1.3.1 - Cellular pathological mechanisms of ALS. SOD1 mutations in 
ALS are responsible for proteossome clogging, axonal transport deficits 
enhanced by cytoskeletal disarrangement, endoplasmic reticulum (ER) stress 
and mitochrondrial dysfunction. Mutated SOD1-induced MN retraction will 
compromise the architecture and functionality of the NMJ. Changes in glial cell 
function such as astrocytes and microglia  can promote increased glutamate 
excitoxicity and release of inflammatory factors such as Tumor Necrosis Factor 
α. Other mutations such as C9orf72 repeats can directly change the RNA 




Table 1.3.I - Dysfunctions present in both pre-symptomatic and symptomatic phases of SOD1G93A disease. Information reports 
observations in the cortex, spinal cord and motor neuron/skeletal muscle of this ALS rodent model. 
 Pre-symptomatic Symptomatic 
Cortex 
Increased cortical neuron excitability associated with increase 
persistent Na+ current [29] 
Mitochondrial complex activity decrement may induce energy 
compensation adaptations in the motor cortex  [53] 
Bioenergetic abnormalities at the motor cortex may lead to 
impairment of corticospinal motor afferents activity [42] 
brain and cerebellum atrophy in SOD1G93A rodents 
[48] 
deficient oligodendrocyte regeneration in the motor 
cortex [49] 
Spinal Cord 
Reduced synaptic input from Renshaw cells leads to lower 
inhibitory control of motor neuron firing [35] 
Microglia start to lose synaptic stripping therefore difficulting 
Selective accumulation of aberrant SOD1 complexes 
lead to impaired proteossomal activity [57]  
Activated microglia releases inflammatory mediators 
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neuronal regeneration [54] 
In the embryonic stages MNs display reduced arborization 
accountable for functionally hyperexcitability [27-28] 
Increased microglia expression but not activated microglia [55] 
Astrocytes release toxic factors that increase excitability in spinal 
cord cultures [37] 
Altered functionality of Na+ channels renders MN susceptible to 
faster recovery from inactivation [56] 
Initial astroglyosis at an early symptomatic phase [55] 
triggering chemically induced toxicity [55, 58] 
Mitochondrial dysfunction due to deficient Ca2+ 
buffering, impaired electron transport chain, and 
induction of apoptosis (see[59]) 
Dysfunction of astrocytic EAAT2 thus contributing to 
glutamate excitotoxicity [60] Oligodendrocytes display 




Axonal transport impairment in susceptible MNs by mutant SOD1 
interaction with the dynein-dynactin complex [61] 
Increase of GluR1 and decrease of GluR2 and CB1 receptor 
trafficking in MNs [36] 
Decreased intracellular Ca2+ clearance in MNs [63] 
Impairment of skeletal muscle metabolism may account 
for failure in energy homeostasis [64] 
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Significant end-plate denervation with fast- over slow- fatigable 
fiber preference [41]  
Gait abnormalities [52]  and atrophy in hindlimb muscles [62] 
Enhancement of NMT [31] 
 
Presence of a mixed population of NMJs with one 
group having decrease ACh release [31] 
Degeneration of neuromuscular synapses and axonal 
retraction [65]   
Significant decrease in the number of motor units [28] 
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1.4. Neuromuscular transmission in ALS: a potential future target?  
 Since ALS is a progressive neurodegenerative disease affecting MNs, 
NMT eventually becomes altered. In fact, several morphological and functionally 
changes in NMJ homeostasis have been identified in both SOD1G93A model 
[31, 41] and humans [66-68]. Therapies targeting the synapse between motor 
terminals and end-plates have displayed some success in the rodent model 
(see [69]), and the study of  NMT is a common assessment of treatment 
effectiveness [70-71].  
 It is with high priority that one must emphasize NMT modulation as an 
hypothetical therapeutic strategy in ALS (see [69]). Taking into account the 
basic principles of cholinergic transmission at the NMJ much can be learn from 
studying this synapse in ALS models. 
 
1.4.1. Basic concepts on neuromuscular transmission 
 The NMJ is the synapse between a MN terminal and a specialized region 
of the muscle fiber designated motor endplate. The action potential (AP) is 
initiated at the ventral horn of the spinal cord and propagates through the axon. 
The electric current reaches the terminal of the MN and activates voltage gated 
calcium channels (VGCC), which are close to release sites, triggering the influx 
of Ca2+ ions into the presynaptic junction. This generates a Ca2+ build-up at the 
terminal activating N-ethylmaleimide-sensitive-factor attachment receptor 
(SNARE) protein complexes and therefore inducing fusion of acetylcholine 
(ACh) containing vesicles (see[72]). ACh is co-transmitted with adenosine-5'-
triphosphate (ATP) that can act as a neuromodulator at P2 receptors and break 
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into adenosine which is also a powerful neuroregulator of ACh release at the 
NMJ [73].  
 The ACh molecules diffuse through the synaptic cleft and reach the 
highly invaginated post-synaptic terminal where they interact with the 
pentameric α1β1ϵγ nicotinic acetylcholine receptors (nAChR). These channels 
are permeable to Na+ and in a less degree to Ca2+. Activation of nAChRs 
generates a flow of current that creates an endplate-potential (EPP). This event, 
if strong enough, may reach a threshold of depolarization sufficient to trigger a 
muscular action potential (AP) leading to fiber contraction. ACh action lasts 1ms 
due to the hydrolytic activity of the acetylcholinesterase enzyme (AChE) that 
converts ACh into choline and acetate (see [72]). 
 Single vesicles can be released spontaneously producing a local 
depolarization - miniature endplate potential (MEPP). If two of more vesicles 
reach the pos-junctional terminal at the same time, a spontaneous depolarizing 
event with larger amplitude than a MEPP occurs – Giant miniature end-plate 
potential (GMEPP). Spontaneous events arise from intracellular Ca2+ store 
mobilization. Since a MEPP corresponds to the amount of ACh molecules per 
vesicle, the ratio between the EPP/MEPP addresses the quantal content (QC), 
i. e., the number of vesicles released per impulse (see [74-75]).  
 
1.4.2. What do we know about neuromuscular transmission 
changes in ALS? 
 Early proof found in muscle preparations of ALS patients, showed 
atrophic groups of fibers and endplate denervation [66, 76] with evidence of 
neuronal collateral sprouting [77-78]. High caliber fibers, with higher energetic 
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demands and large diameter, degenerate first and are re-innervated by low-
caliber fiber terminals [41, 79]. This is also evident in the SOD1G93A mouse 
[41, 62, 80]. Muscle abnormalities result from MN detachment [81] which 
eventually triggers muscle weakness and atrophy. Muscle overexpression of the 
neurite outgrowth inhibitor Nogo-A, hypermetabolism leading to energy deficit 
and signaling deficits account for some of the changes at the NMJ in ALS 
(see[82-83]).   
 Immunoglobulins G (IgGs) from ALS patients increased both evoked and 
spontaneous synaptic transmission at mouse NMJ [67, 84-85] which is 
consistent with the findings in mice expressing human SOD1 mutations [86]. 
These IgGs might be uptake by the presynaptic motor terminal [87] and 
contribute to an increased L-type VGCC blocker sensitivity [88]. These channels 
contribute to an intraterminal increase of Ca2+ levels [89-90]. Deregulation of 
their function, probably as a versatile compensatory mechanism in pathological 
conditions [91], could contribute to Ca2+-mediated excitotoxicity, an hallmark in 
ALS (see [59]). 
 Recent findings from our group explored the NMT physiology in 
SOD1G93A mice diaphragm. Boosted ACh release is present in a pre-
symptomatic stage with transgenic mice displaying increased QC and increased 
MEPP and GMEPP frequency. In the later symptomatic stage, two groups of 
muscle fibers could be separated according to their physiology: one with 
preserved NMT, and other with decreased QC, MEPP and GMEPP frequency 
[31]. This postulates the idea that communication between MNs and muscle 
fibers shifts along disease progression in the SOD1G93A mouse model. 
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Pharmacological modulation of NMT could hypothetically reveal beneficial in 
ALS symptomatology.  
 
1.4.3. A2A adenosine receptors: a role for neuromuscular 
transmission modulation in ALS  
 In a pharmacological context, the variety of pathological mechanisms in 
ALS may favor target variety but as a drawback the treatment may lack 
effectiveness. Riluzole is the only Food and Drug Administration-approved drug 
to treat ALS. It blocks Tretodotoxin-sensitive voltage gated sodium channels 
reducing glutamate release. However this mechanism can mitigate excitotoxicity 
effects prolonging survival only by 2-3 months. One should expect combination 
therapy as a future successful treatment for ALS symptomatology. This urges 
the need for the discovery of new viable drugs [92]. 
 Adenosine receptors are G-protein coupled receptors that modulate 
neurotransmitter release with an high enrollment in pathological conditions. 
There are 4 types of adenosine receptors - A1, A2A, A2B and A3 receptors - that 
control evoked and spontaneous transmitter release by interaction in both 
neurons and glial cells. They are activated by adenosine, which can originate 
from ATP hydrolysis or be released to the extracellular space from the 
cytoplasm through a nucleoside transporter. The A1 (A1R) and A2A (A2AR) 
adenosine receptors are the most prominent P1 neuromodulators in the Central 
Nervous System with a via-à-vis interaction. A1Rs act as depressors of 
neurochemical release by interacting with Gi/o inhibitory proteins leading to a 
lower probability of transmitter release (see [93]). A2ARs positively modulate 
adenlytale cyclase via Gs protein activation which results in an increment of 
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cyclic adenosine monophosphate (cAMP) levels (see [93]). Protein kinase A 
(PKA) activation is dependent on cAMP. Increased activity of PKA due to A2AR 
activation promotes recruitment of P/Q-type VGCC and L-type VGCC [91, 94] 
and negative modulation of K+ channels. The Gs activation can also activate 
phospholipase C (PLC), which cleaves phosphatidylinositol 4,5-bisphosphate 
into diacyl glycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). DAG and Ca2+ 
work together to activate protein kinase C (PKC) a protein that has multiple 
functions ascribed. IP3 can activate receptors in the endoplasmic reticulum 
(ER) triggering intracellular pool recruitment of Ca2+ (see [93, 95]). Therefore 
A2AR activation increases the probability of vesicle release leading to higher 
QC and MEPP frequency [96]. 
 Both receptors are present at the presynaptic junction terminal and 
modulate ACh release [97]. A1R decreases the cholinergic input while A2AR 
boosts NMT especially during high-frequency stimulation [91, 98]. In infant rats 
A2ARs have a preferentially tonic activation over A1R [96] a feature that shifts 
through ageing [99]. A2AR also facilitate Brain-Derived Neurotrophic Factor 
actions at the rat NMJ [100].  
 During the denervation processes of ALS, L-type VGCC recruitment may 
occur [88] and IgGs from ALS patients can promote Ca2+ recruitment trough 
activation of IP3 and ryanodine receptors (RyR) in MN terminals [101]. Since 
A2AR activation increases the safety margin at mammalian NMJ (i.e. more 
quanta release per nerve impulse than the necessary to trigger an AP) specially 
via VGCC recruitment and intracellular store mobilization [102], this receptor 
could be a valid target for slowing ALS symptomatology. Near-symptomatic 
administration of CGS 21680 (a selective A2AR agonist) in SOD1G93A mice 
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increased lifespan and motor performance and postponed disease onset by 12 
days [103]. Chronic administration of caffeine (a non-selective antagonist of 
adenosine receptors) at a similar stage of ALS progression, led to reduced 
lifespan in the same rodent model highlighting the role of A2ARs in ALS [104].  
 With the development of adenosine-related drugs in the clinical field (see 
[105]) and since A2ARs display a specific therapeutic window for 
neuroprotection in neurodegenerative diseases such as Parkinson and 
Huntington diseases (see [106]), one should consider adenosinergic modulation 





 Our goal was to functionally assess how the NMT is changed by A2AR 
activation in high [Mg2+] paralyzed SOD1G93A mouse phrenic nerve-
hemidiaphragm preparations. After validating high [Mg2+] as a tool to study NMT 
modulation in this ALS model, we pharmacologicaly evaluated A2AR 
functionality through an electrophysiological approach. In order to understand 
the ALS spectrum of symptom evolution, we conducted the study in both pre-
symptomatic and symptomatic stages of the SOD1G93A mouse model in 





3.1. Animal model 
 The SOD1G93A mouse model developed by Guerney et al. [17] was 
used in this study. This is the best-characterized mouse model of ALS and thus 
the most widely used in research. Mice of this model carry a high copy number 
(25±1.5) of the human SOD1 gene (transgene) with an autossomical point 
mutation(glycine93→alanine) which confers an enzymatic toxic gain-of-function 
responsible for the biological hallmarks of ALS (see [107]). 
 Transgenic B6SJL-TgN (SOD1-G93A)1Gur/J males (Jackson 
Laboratory, No. 002726) and wild-type B6SJLF1/J females were purchased 
from The Jackson Laboratory (Bar Harbor, ME, USA) and were breed at IMM 
rodent facilities where a colony was established.  Mice were maintained on a 
background B6SJL by breeding SOD1G93A transgenic males with non-
transgenic females in a rotational scheme. Males were crossed with non-
transgenic females because transgenic females are infertile. F1offspring was 
used in all experiments. 4-6 and 12-14 weeks old (wo) wild type (WT) animals 
served as controls. SOD1G93A mice were used to study pre-symptomatic (4-6 
wo) and symptomatic (12-14 wo) phases of the disease. Progeny was no longer 
used in breeding to avoid mSOD1 gene copy number loss and therefore 
deviation from ALS phenotype [17]. 
 Littermates were identified by dermal ear punching and divided into 
cages by gender. This method does not require anesthesia and guarantees 
animal welfare. The ear tissue was used to genotype the animals. Animals were 
housed 4-5 mice/cage, under a 12h light/12h dark cycle, and received food and 
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water ad libitum. Animals were handled according to European Community 
guidelines and Portuguese Law on Animal Care. 
 
3.1.1. Genotyping 
A polymerase chain reaction (PCR) was conducted on a routine basis to 
differentiate non-transgenic from SOD1(G93A) transgenic mice in the progeny. 
The process of genotyping involved several steps namely, DNA extraction, PCR 
and electrophoresis of PCR products. Wild-type mice present a unique band of 
324pb corresponding to the internal positive control. Transgenic mice exhibit an 
additional band of 236pb corresponding to the SOD1 transgene. Regularly, for 
quality control purposes, the copy number of F1 transgenic mice was checked 
through Real time-PCR. 
 
3.2. Electrophysiological Intracellular Recordings 
3.2.1. Phrenic-nerve hemidiaphragm preparation  
 Animals were anaesthetised using halothane and rapidly decapitated. 
Both right and left phrenic-nerve hemidiaphragms were isolated. One 
preparation was placed and stretched in a 3mL Perspex chamber (figure 3.2.1) 
continuously perfused via a roller pump (3mL.min-1) with a physiologic saline 
solution modified from Krebs and Henseleit (1932) [108](NaCl 117mM; KCl 
5mM; NaHCO3 25mM; NaH2PO4 1.2mM; glucose 11mM; CaCl2 2.5mM; MgCl2 
1.2mM; pH 7,4) continuously gassed with 95% O2 and 5% CO2 kept at room 
temperature (22-25ºC). Muscle stretch does not affect transmitter release at 
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diaphragm endplates [109]. The other phrenic-nerve hemidiaphragm 
preparation was kept in a beaker with the saline solution continuously 
carbogenized until it was mounted in the chamber for experiment. 
 
Figure 3.2.1 – schematics of the phrenic-nerve hemidiaphragm preparation in 
the Perspex chamber. Ribs are isolated together with the muscle and neuronal 
tissue to help support the preparation in the apparatus. Strings tied to the ribs 
and to the connective tissue at the end of the hemidiaphragm are used to 
stretch the preparation in order to avoid mechanical instability and increase 
muscle surface area. 
 
3.2.2. Electrophysiological setup and intracellular recordings 
 The phrenic-nerve was stimulated supramaximally by a suction electrode 
(Cu/Cu2+) connected to a S48 square pulse stimulator (Grass Tecnologies, 
West Warwick, RI, USA). In order to mimic physiologic conditions of evoked 
activity, stimuli were applied in a low frequency of 0.5 Hz with a current duration 
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of 20 µs. Stimulations higher than 1 Hz may induce changes in functional 
plasticity [110-111]. The reference electrode was an Ag-AgCl pellet placed in 
the bath. The recording electrode was a glass microelectrode filled with KCl (3 
M) with resistance between 15-40 MΩ inserted in the motor endplate site. A 
Digidata 1440A digitizer (Molecular Devices, Sunnyvale, CA, USA) designed to 
work with the Axoclamp 2B amplifier (Molecular Devices, Sunnyvale, CA, USA) 
performed data acquisition (figure 3.2.2). This allowed continuous monitoring 
and digital storage of EPPs, MEPPs, GMEPPs and resting membrane 
parameters with adequate software (pCLAMP 10.3, Molecular Devices, 
Sunnyvale, CA, USA). 
 
Figure 3.2.2 – Representation of the electrophysiology setup. An interface 
converts digital signal sent from the computer into analog allowing the 
stimulator to send command signals. It delivers a direct current through a 
stimulus isolator resulting in supramaximal square pulses of 20 µs at 0.5 Hz 
through a stimulating suction electrode. The reference electrode placed in bath 
allows the measurement of electric activity and resting membrane potential by 
the recording electrode placed close to the NMJ (<100 µM) [112]. These signals 
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are sent to the amplifier and then converted into a digital format by the digitizer 
allowing acquisition by the adequate software. 
 
3.2.3. Increase of Mg2+ concentration to block muscle contraction 
 Muscle twitch can be blocked using 3 pharmacological strategies: (1) 
submaximal concentrations of tubocurarine which acts as a nAChR blocker 
allowing visualization of the EPP but not spontaneous activity[113]; (2) 
increasing the concentration of Mg2+ leading to a lower probability of vesicle 
release[114]; (3) application of μ-conotoxin GIIIB which inhibits muscle type 
sodium channels preventing the occurrence of an action potential and 
preserving the QC [115].In this work, Mg2+ was added to the physiologic 
solution to block contraction since this divalent ion can compete with Ca2+ in 
order to lower intraterminal Ca2+ influx and therefore keep the EPP below the 
threshold [114]. Since evoked release is highly dependent on Ca2+ micro- and 
nanodomains build-up at the presynaptic terminal[116], a fine-tuned [Mg2+] 
ensures the release of enough vesicles to visualize an EPP without the risk of 
triggering an AP. One must emphasize that it is expected that the increase in 
[Mg2+] does not significantly change the frequency nor the amplitude of 
spontaneous events [117], since they are mainly dependent on intracellular 
Ca2+ stores mobilization [118]. 
 In animals 4-6 wo [Mg2+] ranged between 18.5-19.5 mM. Higher 
concentrations resulted in EPPs lower than 1mV which could be more prone to 
signal contamination and a potential bias in data off-line analysis. Contraction in 
42 
 
older animals (12-14 wo) was blocked by 20.0-22.0 mM of magnesium (figure 
3.2.3). 
 
Figure 3.2.3 – representation of the possible evoked events displayed at 
stimulated NMJs while determining a fine range of [Mg2+] to block contraction. 
(A) low concentrations of Mg2+ (<18.5 mM in 4-6 wo and <20.0 mM in 12-14 wo 
animals) can lead to EPPs in some fibers reaching the threshold to trigger an 
AP not allowing a stable resting membrane potential and the fiber twitch can 
crush the tip of the glass microelectrode; (B) the specific range of [Mg2+] for 
each phase of the study, in the large majority of the fibers, leads to EPPs 
greater than 1 mV and lower than 5 mV and a stable membrane potential; (C) 
concentrations too high of the Ca2+ competitor (>19.5 mM in 4-6 wo and >22.0 
mM in 12-14 wo animals) will result in EPPs lower than 1 mV which difficults 
drug assay. 
 
3.3. Electrophysiological parameters 
 Cell viability and recording precision was determined by 3 important 
factors: (1) stable resting membrane potential throughout all experiment without 
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less than 5% variation of its initial value. Fibers with a resting potential between 
-65 to -85 mV were chosen; (2) basal noise lower than the amplitude of any 
spontaneous event at the recording fiber; (3) mean EPP amplitude constant 
before adding any drug. Clogging of the recording electrode was denounced by 
increase in basal noise, change in electrode resistance, and sudden shift in 
resting membrane potential. A brief pulse of current could be used to unclog the 
electrode and if all the parameters remained stable before the obstruction of the 
tip of the glass micropipette the experiment could continue.  
3.3.1. Evoked activity 
 EPPs were evaluated as the average of the amplitude of 60 consecutive 
EPPs with amplitude ranging between 1mV to 5 mV. The mean of the average 
of the EPP amplitude in the last 10 minutes before adding any drug were 
compared with the last 10 minutes of drug perfusion to evaluate the percentage 
of drug effect. Drug perfusion lasted 34 to 40 minutes. 
 QC can be used to indicate the number of vesicles released per evoked 
impulse. In Mg2+ blocked preparations QC is generally less than 5 and the 
accuracy of its calculation carries no small fluctuations [117]. It is calculated by 
the ratio between the mean EPP amplitude and the mean MEPP amplitude 
acquired during the same period with the same resting membrane potential.  
 
3.3.2. Spontaneous activity 
 MEPPs were recorded in gap-free intervals of 100 seconds before 
adding the drug and at the end of drug perfusion. MEPP threshold of detection 
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was set between 0.2 mV and 1.5 mV (see section 4.1.1.2 and 4.1.2.2). In these 
periods amplitude was defined as the mean of all spontaneous events and the 
frequency as the number of events. 
 Since GMEPP amplitude is at least the double of a MEPP amplitude 
[119], the minimum GMEPP threshold amplitude was set in 1.5 mV (see section 
4.1.1.2 and 4.1.2.2). This indirect measure of spontaneous activity synchronism 
was analyzed as the frequency of giant events in the 100 seconds gap-free 
acquisition mode and the mean amplitude as the average of GMEPP magnitude 
in the same interval. 
 In the analysis of the NMT physiology of in high [Mg2+] paralyzed 
preparations (section 4.1), we also studied the rise and decay times and area of 
both GMEPPs and MEPPs. MEPP rise and decay times are also punctually 
explored in the A2AR modulation study (see section 4.2.1.2).  
 In the off-line analysis a Gaussian lowpass filter (-3dB cutoff = 600 Hz) 
was applied and electric interference was removed using the Clampfit software 
(Molecular Devices, Sunnyvale, CA, USA) (figure 3.3.1). After exporting the 
data file to an integer format, frequency, amplitude, rise and decay times and 





Figure 3.3.1 – several filters applied in the off-line analysis of spontaneous 
events. (A) signal without any filter; (B) signal with a lowpass filter applied and 
(C) plus the removal of electric interference. One can notice that both signal 
amplitude and frequency remain unchanged during this process of digital 
analysis. 
 
Figure 3.3.2 – schematic representation of the timeline of events analyzed 
during an experiment. After having a stable NMJ for at least 20 to 30 minutes, 
spontaneous activity is recorded during 100 sec without stimulation. Then the 
pump inlet tube is transferred from one flask to another to change solutions and 
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start drug perfusion (30 to 40 minutes). This change, if done carefully, does not 
trigger any disturbance to the preparation allowing many changes if needed. 




 To evaluate A2AR modulation, agonist and antagonist were used (see 
table 3.4.I). The A2AR selective agonist (CGS 21680) was perfused alone or in 
the presence of the A2AR antagonist (SCH 58261). The A2AR blocker was 
perfused at least 30 minutes before addition of CGS 21680. All stock solutions 
were made in dimethyl sulfoxide, which is used as a common procedure to 
dissolve compounds for biological assays. To avoid compound precipitation 
aliquots were kept frozen at -20ºC until used [120].  Dimethyl sulfoxide was 
devoid of effect in the performed experiments like previously reported [99-100]. 
Table 3.4.I – Description of the A2AR-related drugs used in this study 




































3.5. Statistical analysis 
 Data is reported as mean ± standard error mean. In the evaluation of the 
physiology of NMT in the presence of high [Mg2+] (section 4.1) the number of 
mice and number of fibers is discriminated. In the A2AR experiments (section 
4.2) each number corresponds to the amount of animals used (1 fiber per 
mouse). 
 In the study of section 4.1, three statistic tests were used: Student's t-test 
for independent samples with normal distributions with homogeneous variances 
(Unpaired t-test); Mann-Whitney U-test when a group displayed a non-normal 
distribution; Student's t-test with Welch's correction whenever variances were 
heterogeneous. Saphiro-Wilk test was used to test normality and homogeneity 
of variances was verified with F-test. Significance was settled at p<0.05 in all 
cases. 
 Non-linear regression was used to underline the differences in MEPP 
amplitude distribution. A gaussian curve best fitted the model. 
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 In section 4.2 to verify differences in drug effect between the two groups 
(WT and SOD1G93A) at the same concentration of the A2AR agonist, the 
Student's t-test for independent samples (Unpaired t-test) was applied. When 
comparing more than 2 means one-way analysis of variance (ANOVA) was 
performed. If p<0.05, Tukey’s pos-test was applied to compare drug-induced 
changes between different groups. Student’s t-test for paired samples (Paired t-
test) was applied to compared obtained data with the measured parameter 
before adding the drug (e.g. EPP mean amplitude before CGS 21680 
















4.1. Physiology of the neuromuscular transmission in SOD1G93A mice 
in the presence of high [Mg2+] 
 We first accessed the physiology of the NMT in the presence of high 
[Mg2+]. Our purpose was to verify if changes in the Ca2+/Mg2+ ratio interfered 
with the evoked or spontaneous release of ACh in 4-6 wo and 12-14 wo animals 
previously characterized by our group with µ-conotoxin GIIIB paralyzed 
preparations [31].  
4.1.1. Pre-symptomatic phase 
4.1.1.1. Evoked activity 
 Evoked response (QC and EPP) results are illustrated in table 4.1.I. EPP 
amplitude in WT (2.19±0.18mV) was not statistically different to that displayed 
by pre-symptomatic transgenic mice (2.23±0.16mV) (p>0.05 Unpaired t-test). 
The QC was also statistically identical between both groups of animals 
(2.96±0.20 in WT and 2.81±0.18 in SOD1G93A mice) (p>0.05 Unpaired t-test). 
The resting membrane potential was close to -75mV (see section 4.1.1.2). 
Table 4.1.I – Evoked activity of 4-6 wo WT and pre-symptomatic SOD1G93A 
mice in the presence of high [Mg2+]. 
 4-6 wo mice 





EPP (mV) 2.19±0.18 2.23±0.16 





4.1.1.2. Spontaneous activity 
 MEPPs and GMEPPs can be differentiated based on their amplitude 
[119]. Figure 4.1.1A displays the frequency histogram of the amplitude of all 
spontaneous events in both WT and SOD1G93A mice. These events fit in a 
Gaussian curve (figure 4.1.1B) like previously described [31] (R2=0.92 for WT 
and R2=0.92 for SOD1G93A). According to this non-linear regression analysis, 





Figure 4.1.1 – (A) frequency histogram of distributed spontaneous events from 
WT and SOD1G93A mice. Events between 0.6 and 0.8 mV are the most 
frequent; (B) Gaussian distribution of the amplitude from spontaneous events in 
both animal groups (n=18, 29 fibers, WT; n=22, 34 fibers, SOD1G93A) 
 Table 4.1.II displays the parameter analysis from spontaneous activity in 
4-6 wo animals. Resting membrane potentials were relatively close to -75mV in 
both animal groups (-75.96±0.97mV, WT; -77.36±0.69mV, SOD1G93A). MEPP 
frequency was not different in both groups (0.97±0.06s-1, WT; 0.96±0.06s-1, 
SOD1G93A; p>0.05 Mann-Whitney U-test) but MEPP amplitude was 
significantly increased in SOD1G93A mice (0.828±0.036mV, WT; 
0.940±0.03mV, SOD1G93A; p<0.05 following Unpaired t-test). Rise and decay 
times in WT mice (2.79±0.10ms) when compared with SOD1G93A mice 
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(2.70±0.07ms) together with MEPP decay time (11.50±0.3 ms, SOD1G93A; 
12.35±0.40ms, WT) were not statistically different (p>0.05 Mann-Whitney U-
test). MEPP area evidenced no significant variation when comparing both 
groups (4.25±0.21, WT; 4.07±0.16, SOD1G93; p>0.05 Mann-Whitney U-test). 
 Regarding GMEPPs, table 4.1.II shows that these events were present in 
20 out of 29 fibers studied in WT mice (≈69%). In SOD1G93A mice the number 
of muscle fibers with GMEPPs was slightly higher, with 26 of the 34 fibers 
analyzed (≈76%) having spontaneous post-synaptic potentials where 2 or more 
ACh vesicles reached the post-synaptic terminal simultaneously. GMEPP 
amplitude (1.904±0.068mV, WT; 1.885±0.070mV, SOD1G93A) and frequency 
(0.09±0.03s-1, WT; 0.11±0.03s-1, SOD1G93A) did not differ significantly 
between both groups (p>0.05 Unpaired t-test). The GMEPP rise time was 
significantly slower in WT mice (4.31±0.40ms) than in SOD1G93A mice 
(3.19±0.20ms) (p<0.05 Student's t-test with Welch's correction). GMEPP area in 
SOD1G93A mice (9.47±0.78), was higher than WT mice (11.90±1.11) (p<0.05 
Mann-Whitney U-test). 
Table 4.1.II – Spontaneous activity of pre-symptomatic SOD1G93A mice and 4-
6 wo WT mice in the presence of high [Mg2+]. 
 4-6 wo mice 








MEPP frequency (s-1) 0.97±0.06 0.96±0.06 
MEPP amplitude (mV) 0.828±0.036 0.940±0.03* 
MEPP Rise Time (ms) 2.79±0.10 2.70±0.07 
MEPP Decay Time (ms) 12.35±0.40 11.50±0.32 
MEPP Area 4.25±0.21 4.07±0.16 
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*p<0.05 Unpaired t-test 
#
p<0.05 Student’s t-test with Welch's correction 
+
p<0.05 Mann-Whitney U-test 
 
4.1.2. Symptomatic phase 
4.1.2.1. Evoked activity 
 We can observe in table 4.1.III that EPP amplitude did not significantly 
differ between WT and SOD1G93A groups (2.66±0.25mV, WT; 2.91±0.25mV, 
SOD1G93A; p>0.05 Unpaired t-test). QC was slightly increased in SOD1G93A 
mice (4.42±0.33) when compared to WT (3.93±0.37) but not significantly 
(p>0.05 Mann-Whitney U-test). Resting membrane potential was close to -
75mV (see section 4.1.2.2). 
Table 4.1.III - Evoked activity of 12-14 wo WT and symptomatic SOD1G93A 





Nº of fibers with GMEPPs 20 26 
GMEPP amplitude (mV) 1.904±0.068 1.885±0.070 
GMEPP frequency (s-1) 0.09±0.03 0.11±0.03 
GMEPP Rise Time (ms) 4.31±0.40 3.19±0.20# 
GMEPP Decay Time (ms) 17.62±1.34 15.57±1.22 
GMEPP Area 11.90±1.11 9.47±0.78+ 
 12-14 wo mice 





EPP (mV) 2.66±0.25 2.91±0.25 
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4.1.2.2. Spontaneous activity 
 Figure 4.1.2A represents the histogram of the distribution of the 
amplitude of all spontaneous events analyzed in 12-14 wo animals. A shift 
between WT and SOD1G93A mice spontaneous activity amplitude can be 
observed in the Gaussian curve (figure 4.1.2B), evidenced by a pronounced 







Figure 4.1.2 – (A) histogram representation of 12-14 wo WT and symptomatic 
SOD1G93A mice spontaneous events amplitude; (B) Gaussian curve 
representing the distribution of spontaneous events, showing a skewing to the 
right in WT events when compared to SOD1G93A distribution; (n=19, 24 fibers, 
WT; n=16, 22 fibers, SOD1G93A). 
 Comparing these groups (table 4.1.IV), we can observe that SOD1G93A 
mice had statistically lower MEPP amplitude than WT mice (0.907±0.044mV, 
WT; 0.663±0.05mV, SOD1G93A; p<0.05 Mann Whitney U-test). MEPP 
frequency is higher in 12-14 wo WT mice (1.52±0.46s-1, WT; 1.07±0.16s-1, 
SOD1G93A; p<0.05 Mann Whitney U-test) and MEPP area is decreased in 
transgenic mice (4.09±0.25, WT; 3.05±0.22, SOD1G93A; p<0.05 Unpaired t-




groups (p>0.05 Mann-Whitney U-test). 15 out of 24 fibers analyzed from WT 
animals (≈63%) had GMEPPs while only 6 of the 22 fibers from SOD1G93A 
mice (≈27%) had giant spontaneous events. SOD1G93A mice presented higher 
mean GMEPP amplitude (1.753±0.068mV, WT; 1.997±0.168mV, SOD1G93A), 
mean decay time (15.15±0.96ms, WT; 18.71±3.88ms, SOD1G93A) and mean 
area (8.28±0.51, WT; 9.16±0.42, SOD1G93A) but without statistical significance 
(p>0.05 Unpaired t-test). GMEPP rise time was significantly different between 
both groups (2.95±0.32ms, WT; 5.29±0.65ms; SOD1G93A; p<0.05 Unpaired t-
test). 
 
Table 4.1.IV - Spontaneous activity of symptomatic SOD1G93A mice and 12-14 
wo WT mice in the presence of high [Mg2+] 
*
p<0.05 Unpaired t-test 
+p<0.05 Mann-Whitney U-test 
 12-14 wo mice 





Resting membrane potential 
(mV) -75.96±0.97 -77.36±0.69 
MEPP frequency (s-1) 1.52±0.46 1.07±0.16+ 
MEPP amplitude (mV) 0.907±0.044 0.663±0.05+ 
MEPP Rise Time (ms) 2.64±0.11 2.74±0.13 
MEPP Decay Time (ms) 11.13±0.51 10.47±0.43 
MEPP Area 4.09±0.25 3.05±0.22* 
   
Nº of fibers with GMEPPs 15 6 
GMEPP amplitude (mV) 1.753±0.068 1.997±0.168 
GMEPP frequency (s-1) 0.13±0.03 0.07±0.03 
GMEPP Rise Time (ms) 2.95±0.32 5.29±0.65* 
GMEPP Decay Time (ms) 15.15±0.96 18.71±3.88 
GMEPP Area 8.28±0.51 9.16±0.42 
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4.1.3. Comparison between phases 
4.1.3.1. Evoked activity 
 In WT mice, EPP amplitude did not vary statistically between 4-6 and 12-
14 wo animals (2.19±0.18mV, 4-6 wo WT; 2.66±0.25mV, 12-14 wo WT; p>0.05 
Mann Whitney U-test). QC was significantly increased in older animals 
(2.96±0.20, 4-6 wo WT; 3.93±0.37, 12-14 wo WT; p<0.05 Mann Whitney U-test) 
(see table 4.1.VI). 
Table 4.1.VI- Comparison of EPP amplitude and QC between 4-6 and 12-14 wo 
WT mice 
+
p<0.05 Mann-Whitney U-test 
 
 In transgenic mice, both EPP amplitude and QC were significantly 
reduced in pre-symptomatic SOD1G93A mice in comparison with older ALS 
mice (2.23±0.16mV and 2.81±0.18mV, respectively in pre-symptomatic 
SOD1G93A; 2.91±0.25mV and 4.42±0.33mV, symptomatic SOD1G93A; p<0.05 
Mann-Whitney U-test) (see table 4.1.VII). 
 
Table 4.1.VII - Comparison of EPP amplitude and QC between pre-
symptomatic and symptomatic SOD1G93A mice 
 
 
12-14 wo mice 
4-6 wo WT 12-14 wo WT 
n (mice, fiber) (18, 29) (19, 24) 
EPP (mV) 2.19±0.18 2.66±0.25 




p<0.05 Mann-Whitney U-test 
 
4.1.3.2. Spontaneous activity 
Table 4.1.VIII- Comparison of the parameters obtained from spontaneous 
activity analysis of 4-6 and 12-14 wo WT mice 
*p<0.05 Unpaired t-test 
+
p<0.05 Mann-Whitney U-test 
 
 Table 4.1.VIII displays the comparison of the spontaneous activity 
between 4-6 weeks and 12-14 wo WT mice. MEPP frequency was significantly 
increased in older animals (0.97±0.06s-1, 4-6 wo WT; 1.52±0.46s-1, 12-14 wo 
WT, p<0.05 Mann-Whitney U-test). GMEPP area was statistically increased in 
 





n (mice, fiber) (22, 34) (16, 22) 
EPP (mV) 2.23±0.16 2.91±0.25+ 
QC 2.81±0.18 4.42±0.33+ 
 
 
4-6 wo WT 12-14 wo WT 
n (mice, fiber) (18, 29) (19, 24) 
MEPP frequency (s-1) 0.97±0.06 1.52±0.46+ 
MEPP amplitude (mV) 0.828±0.036 0.907±0.044 
MEPP Rise Time (ms) 2.79±0.10 2.64±0.11 
MEPP Decay Time (ms) 12.35±0.40 11.13±0.51 
MEPP Area 4.25±0.21 4.09±0.25 
   
Nº of fibers with GMEPPs 20 15 
GMEPP amplitude (mV) 1.904±0.068 1.753±0.068 
GMEPP frequency (s-1) 0.09±0.03 0.13±0.03 
GMEPP Rise Time (ms) 4.31±0.40 2.95±0.32* 
GMEPP Decay Time (ms) 17.62±1.34 15.15±0.96 
GMEPP Area 11.90±1.11 8.28±0.51+ 
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12-14 wo WT mice (11.90±1.11, 4-6 wo WT; 8.28±0.51, 12-14 wo WT; p<0.05 
Mann-Whitney U-test) and rise time was significantly faster in older animals 
(4.31±0.40ms; 4-6 wo WT; 2.95±0.32ms, 12-14 wo WT; p<0.05 Unpaired t-test). 
 
Table 4.1.IX- Comparison of MEPP evaluated parameters between pre-
symptomatic and symptomatic SOD1G93A mice 
*p<0.05 Unpaired t-test 
#
p<0.05 Student’s t-test with Welch's correction 
 
 In ALS mice, symptomatic SOD1G93A animals presented significantly 
lower MEPP amplitude than pre-symptomatic SOD1G93A mice (0.940±0.03mV, 
pre-symptomatic SOD1G93A; 0.663±0.05mV, symptomatic SOD1G93A; p<0.05 
Student’s t-test with Welch's correction) and smaller MEPP area (4.07±0.16, 
pre-symptomatic SOD1G93A; 3.05±0.22, symptomatic SOD1G93A, p<0.05 
Student’s t-test with Whelch’s correction) (see table 4.1.IX). 
 SOD1G93A 





Resting membrane potential 
(mV) 
-77.36±0.69 -77.36±0.69 
MEPP frequency (s-1) 0.96±0.06 1.07±0.16 
MEPP amplitude (mV) 0.940±0.03* 0.663±0.05# 
MEPP Rise Time (ms) 2.70±0.07 2.74±0.13 
MEPP Decay Time (ms) 11.50±0.32 10.47±0.43 
MEPP Area 4.07±0.16 3.05±0.22# 
   
Nº of fibers with GMEPPs 15 (24) 6 (22) 
GMEPP amplitude (mV) 1.753±0.068 1.997±0.168 
GMEPP frequency (s-1) 0.13±0.03 0.07±0.03 
GMEPP Rise Time (ms) 2.95±0.32 5.29±0.65*  
GMEPP Decay Time (ms) 15.15±0.96 18.71±3.88 
GMEPP Area 8.28±0.51 9.16±0.42 
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 Regarding GMEPPs, overall comparison between pre- and symptomatic 
SOD1G93A mice suggested a higher prevalence of GMEPPs in the former 
(≈63% versus 27% in symptomatic SOD1G93A) and slower GMEPP rise time in 
symptomatic SOD1G93A mice (2.95±0.32ms, pre-symptomatic SOD1G93A; 
5.29±0.65ms, symptomatic SOD1G93A; p<0.05 Unpaired t-test) (see table 
4.1.IX). 
 
4.2. Effect of adenosine A2A receptors on the neuromuscular 
transmission of ALS mice 
 The A2AR functionality was assessed in both phases of disease 
progression in pre- and symptomatic SOD1G93A mice and in 4-6 wo and 12-14 
wo WT mice. In order to evaluate how A2AR modulate NMT at phrenic-nerve 
hemidiaphragm preparations, we performed dose-response experiments with 
the A2AR selective agonist CGS21680 [121] at 3, 5 and 10 nM in WT and 
SOD1G93A mice. We used CGS 21680 (25nM) in the older groups of rodents 
(12-14 wo animals) to unveil if A2AR facilitation could be augmented at 
concentrations higher than 10nM (see section 4.2.2).  
4.2.1. Pre-symptomatic phase 
4.2.1.1. Evoked activity 
 Figure 4.2.1A displays the effect of CGS21680 in EPP amplitude at the 3 
tested concentrations i.e. 3, 5 and 10 nM. At 3nM the A2AR agonist displayed a 
higher facilitation in SOD1G93A (16.60±2.73%, n=5) than WT mice 
(8.97±1.85%, n=7) but no statistical significance was found (p>0.05 Unpaired t-
test). Using 5 nM of CGS21680, NMT was largely enhanced in transgenic 
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animals when compared to WT (8.54±1.24% n=8, WT, 26.56±3.33%, n=15, 
SOD1G93A, p<0.05 Unpaired t-test). The same feature was present when 10 
nM of CGS21680 was applied (5.59±0.99%, n=4, WT, 19.19±4.07%, n=5, 
SOD1G93A, p<0.05 Unpaired t-test). When using 5 nM of CGS 21680, EPP 
increase in the SOD1G93A group was higher than in the other concentrations 
(3 and 5nM of CGS 21680). In WT mice CGS 21680 effect was similar at 3 and 
5 nM but slightly decreased at 10 nM. However differences in concentration-
dependent effect were not significantly different within the same group (p>0.05 
one-way ANOVA). Taking this into account, we selected CGS 21680 at 5nM 
whenever a more profound study of the A2AR functionality was needed in 4-6 
wo mice (e.g. evaluation of the A2AR antagonist effect). Due to a typical 
patchiness in CGS 21680 responses on NMT [97] a higher number of 
experiments was performed at this concentration. In figure 4.2.1B we can see 
the different effect in EPP amplitude upon A2AR activation by CGS21680 
(5nM), in both WT and SOD1G93A groups throughout drug perfusion.  
 In order to determine if the observed effect was via A2AR activation, we 
used the A2AR antagonist (SCH 58261) [122] combined with 5nM of the A2AR 
agonist. In 4-6 wo WT animals, SCH 58261 (50nM) exhibited no significant 
effect in EPP amplitude (-2.33±1.58%, n=5; p>0.05 Paired t-test) and effectively 
blocked CGS21680 (5nM) effect (2.27±1.10%, n=5) (p<0.05 one-way ANOVA 
followed by Tukey’s pos-hoc) (see figure 4.2.1C). In SOD1G93A animals, the 
A2AR antagonist effect was null (2.00±1.05%, n=6; p>0.05 Paired t-test) and 
significantly blocked A2AR facilitation by CGS21680 (5nM) (0.39±1.17%, n=5) 
(p<0.05 one-way ANOVA followed by Tukey’s pos-hoc). These results ensured 
that CGS21680 action was trough A2AR activation.  
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Figure 4.2.1- (A) dose-response change in EPP amplitude in the presence of 
CGS21680 (3 nM: n=7, WT, n=5, SOD1G93A; 5nM: n=8, WT, n=15, 
SOD1G93A; 10nM: n=4, WT, n=5, SOD1G93A); (B) representative averaged 
changes in EPP amplitude in the presence of 5nM of CGS 21680 (n=4, WT, 
n=6 SOD1G93A); (C) bar-representation of CGS 21680 (5nM) and SCH 58261 
(50nM) interaction in EPP amplitude (SCH 58261 at 50 nM:  n=5, WT, n=6, 
SOD1G93A; CGS 21680 (5nM) in the presence of SCH 58261 (50nM): n=5, 
WT; n=5, SOD1G93A); § Paired t-test (as compared with mean EPP amplitude 
before drug perfusion); ∂p<0.05 one-way ANOVA followed by Tukey’s pos-hoc, 
*p<0.05 Unpaired t-test.  
 QC increase in SOD1G93A was higher than in WT in all concentrations 
of CGS 21680 (Figure 4.2.2A). QC was significantly higher in transgenic when 
C 
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compared to WT animals at 3nM (9.41±3.22%, n=5, WT, 21.20±1.78%, n=4, 
SOD1G93A), 5 nM (9.46±2.20%, n=8, WT, 27.73±4.15%, n=10, SOD1G93A) 
and 10 nM of the A2AR agonist. (4.61±1.23%, n=4, WT, 22.29±6.07%, n=4, 
SOD1G93A) (p<0.05 Unpaired t-test). At 3, 5 and 10nM of CGS 21680, QC was 
significantly different from control situation (mean QC before adding the drug), 
however in WT mice this was only evident when 3 and 5nM of the drug were 
applied (p<0.05 Paired t-test).   
 SCH 58261 at 50 nM significantly blocked the CGS21680 effect on QC 
increase in WT (-2.01±1.30%, n=4) and SOD1G93A mice (0.88±1.73%, n=6) 
(p<0.05 one-way ANOVA followed by Tukey’s pos-hoc) and per se was devoid 
of effect in QC in both phenotypes (-1.83±3.34%, n=4, WT, 3.16±1.13%, n=5, 








Figure 4.2.2 – (A) Variation in QC promoted by CGS 21680 in WT and 
SOD1G93A mice (3nM: n=5, WT, n=4, SOD1G93A; 5nM:  n=8, WT, n=10, 
SOD1G93A; 10nM: n=4, WT, n=4, SOD1G93A); (B) bars elucidative of the 














































































n=5, SOD1G93A; CGS 21680 (5nM) in the presence of SCH 58261 (50nM): 
n=4, WT, n=6, SOD1G93A); § Paired t-test (as compared with mean QC before 
drug perfusion), ∂p<0.05 one-way ANOVA followed by Tukey’s pos-hoc, *p<0.05 
Unpaired t-test.   
4.2.1.2. Spontaneous activity 
 MEPP amplitude was not significantly changed by the A2AR receptor 
selective agonist CGS 21680 in 4-6 wo animals (p>0.05 Paired t-test) (figure 
4.2.3A). No significant differences were found between groups at 3 nM 
(0.15±2.58%, n=6, WT, 1.76±4.28%, n=5,  SOD1G93A), 5 nM (1.29±1.98%, 
n=12, WT, 2.98±0.91%, n=12, SOD1G93A) and 10 nM (2.11±3.46%, n=7, WT, -
2.17±2.18%, n=5, SOD1G93A) of CGS 21680 (p>0.05 Unpaired t-test).  
 SCH 58216 (50nM) did not statistically change MEPP amplitude 
(0.99±3.27%, n=5, WT; 1.45±1.75%, n=4, SOD1G93A; p>0.05 Paired t-test) 
and therefore no differences were found between different drug perfusions 
(p>0.05, one-way ANOVA) (figure 4.2.3B).  
 Figure 4.2.3C illustrates the effect of CGS 21680 in MEPP frequency. 
MEPP frequency was did not statistically change in WT (p>0.05 Paired t-test) as 
opposite of SOD1G93A mice (p<0.05 Paired t-test). At 3nM the A2AR-mediated 
increase in MEPP frequency did not significantly change between WT and 
SOD1G93A animals (14.55±7.26%, n=6, WT, 29.59±11.44%, n=5; p>0.05 
Unpaired t-test). With 5 nM, SOD1G93A mice had significantly increased 
facilitation of MEPP frequency than WT mice (6.36±3.79%, n=12, WT, 
23.13±7.03%, n=12, SOD1G93A; p<0.05 Unpaired t-test). CGS 21680 (10nM) 
effect on MEPP frequency was slightly lower in SOD1G93A (7.10±4.35%, n=7) 
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when compared to WT animals (26.87±12.13%, n=5) but this difference was not 
statistically different (p>0.05 Unpaired t-test). 
 To confirm that the effect of CGS 21680 was through A2AR activation, its 
action was evaluated in the presence of the A2AR selective antagonist, SCH 
58261 (50nM). Alone, SCH 58261 did not change MEPP frequency in both 
groups of mice (2.40±2.29%, n=5, WT, 1.18±3.54%, n=4, SOD1G93A; p>0.05 
Paired t-test). In the presence of the A2AR antagonist (SCH 58261) at 50 nM 
(figure 4.2.3D), the CGS 21680 (5nM) increase in MEPP frequency was 
abolished in SOD1G93A mice (-3.19±0.20%, n=3, p<0.05 one-way ANOVA 
followed by Tukey's pos-hoc) while in WT animals no differences were observed 
(-3.04±1.19%, n=4, p>0.05 one-way ANOVA). This suggests that A2AR act 
presynaptically by modifying the frequency of spontaneous release, which is in 






































































































































































Figure 4.2.3 – (A) Effect of CGS 21680 at different concentrations in MEPP 
amplitude in WT and SOD1G93A mice (3nM: n=6, WT, n=5, SOD1G93A; 5nM: 
n=12, WT; n=12, SOD1G93A; 10nM: n=7, WT, n=5, SOD1G93A); (B) MEPP 
amplitude under the action of SCH 58261 (50 nM) (SCH 58261 (50nM): n=5, 
WT; n=4 SOD1G93A; CGS 21680 (5 nM) in the presence of SCH 58261 
(50nM): n=4, WT, n=3, SOD1G93A); (C) changes in the MEPP frequency of 
both 4-6 wo WT and pre-symptomatic SOD1G93A animals promoted by CGS 
21680 at 3 different concentrations (3, 5 and 10 nM) (3nM: n=6, WT, n=5, 
SOD1G93A; 5nM: n=12, WT; n=12, SOD1G93A; 10nM: n=7, WT, n=5, 
SOD1G93A); (D) SCH 58261 blocked the CGS 21680 increase in MEPP 
frequency (SCH 58261(50nM): n=5, WT, n=4, SOD1G93A; CGS 21680 (5nM) 
in the presence of SCH 58261 (50nM): n=4, WT, n=3, SOD1G93A); §p<0.05 
Paired t-test as compared with MEPP frequency before adding the drug, 





 Since GMEPPs were not very frequent, we could only analyze their 
amplitude and frequency when we tested 5nM of CGS21680 due to the higher 
number of experiments performed at that concentration. GMEPP amplitude 
remained unchanged upon A2AR activation (by CGS 21680 at 5 nM) (p>0.05 
Paired t-test) (figure 4.2.4A). When we compared both WT (0.64±2.57%, n=3) 
and SOD1G93A (0.12± 5.74%, n=3) groups there was no statistical difference 
(p>0.05 Unpaired t-test). GMEPP frequency (figure 4.2.7B) was markedly 
increased in SOD1G93A (107.94±12.99%, n=3) when compared to WT mice 







Figure 4.2.4 – (A) Effect of CGS 21680 (5nM) in GMEPP amplitude in 4-6 wo 
WT (n=3) and SOD1G93A (n=3) mice; (B) GMEPP frequency facilitation upon 
A2AR activation in both groups (n=3, WT, n=3, SOD1G93A); §p<0.05 Paired t-
test as compared with GMEPP frequency before adding the drug; ∂p<0.05 one-










































































4.2.2. Symptomatic phase 
4.2.2.1. Evoked activity 
 In 12-14 wo WT animals we observed an increase in EPP amplitude in all 
tested of concentrations of CGS 21680 (3, 5, 10 and 25 nM), which was 
different from symptomatic SOD1G93A mice as follows: 3nM: 19.33±3.88% 
(n=8) in WT and -8.70±2.02 (n=9) in SOD1G93A mice; 5nM: 20.04±3.27% 
(n=7) in control mice and -6.44±5.20% (n=4) in symptomatic mice; 10nM: 
24.60±6.92% (n=7) in WT and -2.38±3.14% (n=5) in ALS mice; 25nM: 
11.75±1.15% (n=4) in 12-14 wo WT mice and -8.84±11.45% (n=4) in 
SOD1G93A rodents (p<0.05 Unpaired t-test) (figure 4.2.5A). Figure 4.2.5B 
evidences the different EPP amplitude changes in WT and SOD1G93A 
throughout CGS 21680 (5nM) perfusion.   
 Since in WT mice at 10nM we had a higher facilitation of EPP amplitude 
than in the other concentrations (but non-significant, p>0.05 one-way ANOVA), 
we tested the A2AR antagonist SCH 58261 (50nM) in the presence of the 
selective A2AR agonist (CGS 21680) to verify if the observed effect was 
through A2AR activation. SCH 58261 (50nM) blocked the CGS 21680 (10 nM) 
EPP amplitude increase in WT mice (-1.89±6.64%, n=3, p<0.05 one-way 
ANOVA following Tukey’s pos-hoc). The A2AR antagonist did not display any 
effect in EPP amplitude in both WT (-0.24±2.41%, n=3) and SOD1G93A mice (-
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Figure 4.2.5 - A) percentage-change in EPP amplitude from 12-14 wo WT and 
symptomatic SOD1G93A animals after application of CGS 21680 (3 nM: n=8, 
WT, n=9, SOD1G93A; 5nM: n=7, WT, n=4, SOD1G93A; 10nM: n=7, WT, n=5, 
SOD1G93A; 25 nM: n=4, WT, n=4, SOD1G93A;  (B) representative averaged 
changes in EPP amplitude in 12-14 wo and symptomatic mice mice upon A2AR 
activation by CGS21680 (5nM) (n=4, WT, n=4 SOD1G93A); (C) bar graph of 
CGS 21680 (10nM) effect in the presence of SCH 58261 (50nM) (SCH 58261 
(50 nM): n=3, WT, - n=6, SOD1G93A; CGS 21680 (10nM) in the presence of 



















































































































compared mean EPP amplitude before adding the drug, ∂p<0.05 one-way 
ANOVA followed by Tukey’s pos-hoc, *p<0.05 Unpaired t-test. 
 When comparing QC change as a result of A2AR activation, we 
observed that QC was significantly increased in WT mice at 3 nM 
(17.54±6.31%, n=5, WT, -0.24±0.85%, n=5, SOD1G93A), 5 nM (17.56±2.55%, 
n=5, WT, 2.08±3.78%, n=4, SOD1G93A), 10 nM (29.91±5.88%, n=5, WT, -
1.55±3.20%, n=3, SOD1G93A) and 25 nM of CGS 21680 (10.42±2.70%, n=4, 
WT, -9.45±9.98%, n=4) (p<0.05, Unpaired t-test) (figure 4.2.6A). 
 In figure 4.2.6B we can observe that the application of SCH 58261 at 50 
nM blocked the CGS 21680 (10 nM) effect on the QC increase in WT mice (-
5.02±4.85%, n=3, p<0.05 one-way ANOVA followed by Tukey's pos-hoc). The 
A2AR antagonist did not change the QC of both groups (5.07±2.79%, n=3, WT, 








Figure 4.2.6 - (A) evidences a dose-response change in the QC of WT mice 
while in symptomatic mice CGS 21680 had no effect in QC (3 nM: n=5, WT, 




SOD1G93A; 25nM: n=4, WT, n=4, SOD1G93A); (B) CGS 21680 (10 nM) effect 
in WT is blocked by SCH 58261 (50nM) (SCH (50nM): n=3, WT, n=3, 
SOD1G93A; CGS 21680 (10nM) in the presence of SCH 58261 (50nM): n=3, 
WT; n=3, SOD1G93A); §p<0.05 Paired t-test as compared with QC before 
addition of CGS 21680, ∂p<0.05 one-way ANOVA followed by Tukey’s pos-hoc, 
*p<0.05 Unpaired t-test. 
4.2.2.2. Spontaneous activity 
 MEPP amplitude did not significantly change between groups in all tested 
concentrations of CGS 21680 (p>0.05 Paired t-test) and therefore no significant 
changes were found between groups (3nM: -1.84±1.61, n=5, WT, -5.63±3.52%, 
n=5, SOD1G93A; 5nM: 1.12±1.61%, n=5, WT, -5.81±2.54%, n=6, SOD1G93A; 
10nM: 0.68±1.55%, n=6, WT, 1.05±5.60%, n=4, SOD1G93A; 25 nM: 
1.50±2.54%, n=4, WT, -1.42±4.91%, n=4, SOD1G93A; p>0.05 Unpaired t-test) 
(figure 4.2.7A). 
 In Figure 4.2.7B we can observe that SCH 58261 (50nM) did not alter 
MEPP amplitude (p>0.05 Paired t-test) in 12-14 wo innervated muscle fibers 
(SCH 58261 (50nM): 0.61±0.81%, n=6, WT, -8.51±7.46%, n=3, SOD1G93A; 
CGS 21680 (10nM) in the presence of SCH 58261 (50nM): 0.61±0.81%, n=5, 
WT, -8.51±7.46, n=3, SOD1G93A). 
 When perfusing 3nM of CGS 21680, MEPP frequency was 17.04±3.62% 
(n=5) increased in WT mice, it was significantly higher than in SOD1G93A mice 
(-0.27±3.60%, n=5) (p<0.05 Unpaired t-test). MEPP frequency was also 
significantly higher in WT mice at 5nM (24.31±3.60%, n=5, WT, -1.30±5.23%, 









































































3.46±7.78, n=4, SOD1G93A) (p<0.05 Unpaired t-test) (figure 4.2.7C). When 
using 25 nM, WT had an increase of 10.58±5.38% (n=4) significantly different 
from SOD1G93A mice (-16.00±10.27%, n=4) (p<0.05 Unpaired t-test). CGS 
21680 was devoid of effect in symptomatic mice (p>0.05 Paired t-test). 
 In the presence of the A2AR antagonist SCH 58261 (50nM), the increase 
in MEPP frequency by CGS 21680 (10 nM) in WT mice was abolished (-
0.14±5.47%, n=4; p<0.05 one-way ANOVA followed by Tukey’s pos-hoc). SCH 
58261 did not promote any effect in MEPP frequency in both WT (-0.12±1.57, 

































































































Figure 4.2.7 – (A) graphic representation evidencing no changes in MEPP 
amplitude after A2AR activation by CGS 21680 (3nM: n=5, WT, n=5, 
SOD1G93A; 5nM: n=5, WT, n=6, SOD1G93A; 10nM: n=6, WT, n=4, 
SOD1G93A; 25 nM: n=4, WT, n=4, SOD1G93A); (B) effect of CGS 21680 
(10nM), SCH 58261 (50nM) and both drugs applied (SCH 58261 (50nM): n=6, 
WT, , n=3, SOD1G93A; CGS 21680 (10nM) in the presence of SCH 58261 
(50nM): n=5, WT, n=3, SOD1G93A); (C) excitatory concentration-dependent 
effect  of CGS 21680 in MEPP frequency of WT and null effect in symptomatic 
SOD1G93A mice (3nM: n=5, WT, n=5, SOD1G93A; 5nM: n=5, WT, n=6, 
SOD1G93A; 10nM: n=6, WT, n=4, SOD1G93A; 25nM: n=4, WT, n=4, 
SOD1G93A); (D) SCH 58261 (50nM) effectively blocked MEPP frequency 
increase by 10 nM of the A2AR agonist in 12-14 wo WT rodents (SCH 58261 
(50nM): n=5, WT, n=4, SOD1G93A; CGS 21680 (10nM) in the presence of 
50nM of SCH 58261: n=4, WT, n=4, SOD1G93A); §p<0.05 Paired t-test as 
compared with control MEPP frequency before drug perfusion, ∂p<0.05 one-way 
ANOVA followed by Tukey’s pos-hoc, *p<0.05 Unpaired t-test. 
 GMEPP amplitude was not significantly changed by CGS21680 (10nM) 
in both WT (3.04±1.47%, n=3) and SOD1G93A animals (-2.27±6.69%, n=3) 
(figure 4.2.8A) (p>0.05 Paired t-test). GMEPP frequency was statistically 
increased in WT when compared to symptomatic ALS mice in the presence of 
10nM of the A2AR agonist (73.87±19.43%, n=3, WT, 10.16±17.60%, n=3, 















Figure 4.2.8 – (A) bar-chart representation of GMEPP amplitude change by 
CGS 21680 (10nM) (n=3, WT, n=3, SOD1G93A); (B) GMEPP frequency 
variation in the presence of 10nM of CGS 21680 (n=3, WT, n=3, SOD1G93A); 
§p<0.05 Paired t-test as compared with GMEPP frequency before start 
perfusion; ∂p<0.05 one-way ANOVA followed by Tukey’s pos-hoc;*p<0.05 
Unpaired t-test 
 
4.2.3. Comparison between phases 
4.2.3.1. Evoked activity 
 Regarding WT animals, the selective A2AR agonist caused a more 
pronounced excitatory effect in EPP amplitude in older WT (12-14 wo) than in 
younger WT (4-6 wo) animals. This increment was evident at 3, 5 and 10nM of 
CGS 21680 (figure 4.2.9A) (p>0.05 Unpaired t-test). Comparison of EPP 
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amplitude changes between 5nM of A2AR agonist perfusion in 4-6 wo and 12-
14 wo WT can be observed in figure 4.2.9B. 
 An opposite situation occurred in SOD1G93A animals. In pre-
symptomatic ALS mice, CGS 21680 had an excitatory effect in EPP amplitude 
at 3, 5 and 10nM (figure 4.2.9C) but when symptoms started to appear, the 
A2AR agonist did not modify the evoked activity of SOD1G93A mice (p<0.05 













Figure 4.2. 9 – (A) changes in EPP amplitude promoted by CGS 21680 (3, 5 
and 10 nM) in different aged WT animals (4-6 wo WT: 3nM, n=7, 5nM, n=8, 
10nM, n= 4; 12-14 wo WT: 3nM, n=8, 5nM, n=7, 10nM, n=7); (B) representation 
of the EPPs changes (CGS 21680 at 5 nM)  in 4-6 wo (n=4) and 12-14 wo mice 
(n=4); (C) Symptomatic SOD1G93A mice lose their A2AR facilitation when 
A B 
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symptoms start to arise (pre-symptomatic SOD1G93A: 3nM, n=5, 5nM, n=15, 
10nM, n=5; symptomatic SOD1G93A: 3nM, n=9, 5nM, n=4, 10 nM, n=5); (D) 
Averaged changes in EPP amplitude in the presence of CGS 21680 and in the 
different stages of disease progression in SOD1G93A mice (n=6, pre-
symptomatic SOD1G93A; n=4, symptomatic SOD1G93A); §p<0.05 Paired t-test 
as compared with mean EPP amplitude before starting drug perfusion,*p<0.05 
Unpaired t-test 
 
 The QC exhibits the same pattern of changes as EPP amplitude when 
comparing the different stages in both groups of animals (figure 4.2.10). A shift 
in effective concentrations of CGS 21680 effect seemed to occur. In 4-6 wo WT, 
10 nM of the A2AR agonist did not promote a statistical significant increase of 
QC while in older animals (12-14 wo), at this concentration, the facilitation was 









Figure 4.2.10 – (A) An increase in QC facilitation is evident when comparing 
12-14 wo  with 4-6 wo WT mice (4-6 wo WT: 3nM, n=5, 5nM, n=8, 10nM, n= 4; 
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activation in all tested concentrations of CGS 21680 when symptomatology 
arises in SOD1G93A animals (pre-symptomatic SOD1G93A: 3nM, n=4, 5nM, 
n=10, 10nM, n=4; symptomatic SOD1G93A: 3nM, n=5, 5nM, n=4, 10 nM, n=3); 
§p<0.05 Paired t-test as compared with QC before drug perfusion;*p<0.05 
Unpaired t-test 
4.2.3.2. Spontaneous activity  
 MEPP amplitude was not altered by A2AR activation in WT and 
SOD1G93A animals (p>0.05 Paired t-test). MEPP frequency did not vary 
between ages in WT animals at 3 and 10 nM of CGS 21680, but at 5nM it was 
significantly increased in older (12-14 wo) WT animals (p<0.05 Unpaired t-test). 
In SOD1G93A mice, the pre-symptomatic CGS 21680-mediated increase in 
MEPP frequency was lost in the symptomatic stage (p<0.05 Unpaired t-test) 

















Figure 4.2.11- (A) MEPP amplitude does not change in WT animals (4-6 wo 
WT: 3nM, n=6, 5nM, n=12, 10nM, n= 7; 12-14 wo WT: 3nM, n=5, 5nM, n=5, 
10nM, n=6) and (B) SOD1G93A mice (pre-symptomatic SOD1G93A: 3nM, n=5, 
5nM, n=12, 10nM, n=5; symptomatic SOD1G93A: 3nM, n=5, 5nM, n=6, 10 nM, 
n=4), due to A2AR activation by CGS 21680; (C) MEPP frequency changes in 
WT animals (4-6 wo WT: 3nM, n=6, 5nM, n=12, 10nM, n= 7; 12-14 wo WT: 
3nM, n=5, 5nM, n=5, 10nM, n=6) and (D) pre-symptomatic and symptomatic 
SOD1G93A(pre-symptomatic SOD1G93A: 3nM, n=5, 5nM, n=12, 10nM, n=5; 
symptomatic SOD1G93A: 3nM, n=5, 5nM, n=6, 10 nM, n=4) in the presence of 
the referred concentrations of CGS 21680; §p<0.05 Paired t-test as compared 
with control MEPP frequency before drug perfusion;*p<0.05 Unpaired t-test 
 
 GMEPP amplitude was not changed by CGS 21680 in both SOD1G93A 
and WT groups (p>0.05 Paired t-test) (figure 4.2.12A). Regarding GMEPP 
frequency, in WT mice it was statistically increased in 12-14 wo animals when 
compared to 4-6 wo rodents (p<0.05 Unpaired t-test). This comparison was 
made between different concentrations of CGS 21680 (5nM in 4-6 wo mice and 
10nM in 12-14 wo rodents) that elicited increases in GMEPP frequency. In 
SOD1G93A, the raise in GMEPP frequency in the pre-symptomatic stage (CGS 
21680 at 5nM), was lost in symptomatic SOD1G93A mice (CGS 21680 at 10 





















Figure 4.2.12 – (A) A2AR activation effect in GMEPP amplitude in the different 
phases of the disease at the different concentrations of CGS 21680 used (5nM 
in younger animals (4-6 wo) and 10 nM in 12-14 wo mice) (5nM: n=3, 4-6 wo 
WT, n=3, pre-symptomatic SOD1G93A; 10nM: n=3, 12-14 wo WT, n=3, 
symptomatic SOD1G93A); (B) GMEPP frequency was increased in 12-14 wo 
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WT mice when compared to 4-6 wo WT rodents, and the opposite is observed 
in SOD1G93A mice where the GMEPP frequency increase in pre-symptomatic 
animals is lost along disease progression in the presence of the A2AR agonist 
(5nM: n=3, 4-6 wo WT, n=3, pre-symptomatic SOD1G93A; 10nM: n=3, 12-14 
wo WT, n=3, symptomatic SOD1G93A); p<0.05 Paired t-test as compared with 








 The results herein described clearly showed that, in the presence of high 
[Mg2+] and low frequency stimulation (0.5 Hz), the effects of A2AR are 
enhanced in phrenic nerve-hemidiaphragm preparations from pre-symptomatic 
SOD1G93A mice an ALS transgenic model. On the contrary, in the 
symptomatic phase the A2AR effect was lost.  
 
5.1. Principal features of the neuromuscular transmission in 
SOD1G93A mice are maintained in the presence of high [Mg2+] 
 It is well-known that increase in [Mg2+] to avoid muscle fiber contraction 
in intracellular recordings, decreases EPP amplitude and QC [114]. Fine-tuning 
of [Mg2+] in both studied phases of disease progression was done to allow 
electrophysiology recordings, and therefore evoked activity parameters strongly 
deviated from physiologic values [31]. Differences in EPP (only in SOD1G93A) 
and QC when comparing the same group at different ages are evidence of NMJ 
maturation, which is an intrinsic feature in the NMT of these animals. Increased 
MEPP frequency in 12-14 wo WT in comparison to 4-6 wo WT mice also 
supports this idea. Decreased MEPP amplitude and area in symptomatic mice 
in contrast with pre-symptomatic animals, highlighted the neurodegenerative 
events affecting spontaneous ACh release at the NMJ throughout disease 
progression [31]. 
 Regarding pre-symptomatic and age matched WT mice comparisons, 
increased MEPP amplitude and GMEPP amplitude and frequency in pre-
symptomatic rodents are evidence of the increased spontaneous NMT features 
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of the SOD1G93A animal model. When symptomatology arises, MEPP 
frequency, amplitude and area are decreased in SOD1G93A animals by 
contrast with 12-14 wo WT mice. This emphasized the intrinsic impairment 
regarding spontaneous release that symptomatic SOD1G93A mice display [31]. 
It is evident in our work that by using high [Mg2+] to avoid muscle contraction, 
the main features of NMT in SOD1G93A phrenic nerve-hemidiaphragm 
preparations are preserved. This strategy is therefore an useful tool to study 
adenosinergic modulation at the SOD1G93A NMJ. 
 
5.2. A2A adenosine receptors are functionally up-regulated in pre-
symptomatic SOD1G93A neuromuscular junctions  
 QC and EPP amplitude were significantly increased in pre-symptomatic 
SOD1G93A mice when A2AR were activated. Previous work evidenced a 
possible physiological compensatory mechanism leading to increased NMT in 
pre-symptomatic SOD1G93A mice [31]. A2AR are important modulators of NMT 
and upon activation can lead to an increase of ACh release. Since SCH 58261 
(50nM) did not evidence any change in evoked activity, A2AR are not being 
tonically activated in young mice (4-6 wo). In infant rats, A2AR exhibit excitatory 
predominance over A1R inhibitory action [96]. However mice have a different 
physiology in diaphragmatic fibers when comparing to rats. Failures are less 
frequent in mice probably due to a higher proportion of fatigue-resistance fibers 
representative of total muscle diaphragm mass [124]. Since these types of 
fibers are less prone to degeneration in ALS [41], this physiological feature may 
account for an unnecessary constitutive A2AR activation. However, during high 
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frequency stimulation (50Hz) A2AR activation may be important for facilitation of 
ACh release [91]. ALS renders individuals susceptible to tetanic stimuli in a 
gender unspecific manner [125], and therefore A2AR upregulation could be a 
compensatory mechanism to overcome tetanic fade. 
 Adenosine is important in synchronizing transmitter release in oxidative 
stress conditions at the NMJ, therefore enhancing synaptic efficiency. 
SOD1G93A present high levels of reactive oxygen species, and therefore A2AR 
upregulation could account for a compensatory mechanism [126]. In fact 
administration of A2AR agonist CGS 21680 promoted MN survival [127] and 
delayed disease onset [103]. A2AR can promote the recruitment of L-type 
VGCC during repetitive stimulation [91]. In ALS IgGs immunoreactivity renders 
L-type VGCC sensitive to stimuli [88].  Therefore A2AR facilitation via L-type 
VGCC recruitment may be responsible for the observed functional upregulation 
in evoked activity probably by core-vesicle mobilization at the NMJ (see [128]). 
This subtype of VGCC is important in establishing Ca2+ micro and nano-
domains. In SOD1G93A mice there is an increase in intra-terminal [Ca2+] 
probability due to mitochondrial complex dysfunction (see [59]) but also to L-
type VGCC increased recruitment [88]. Use of nitrendipine [L-type VGCC 
blocker] could be a future task towards unveiling this interaction. 
 Other types of VGCC have been implicated with ALS pathogenesis. N-
type VGCC are overexpressed in the motor cortex neurons of SOD1G93A mice 
[129] and are modified by ALS sera together with L-type  VGCC leading to 
increased MEPP frequency [130]. The same is observed regarding P/Q type-
VGCC [131]. Yet, more emphasis is given to L-type channel dysfunction in ALS 
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[88, 129-130, 132]. These channels possess a longer length of activation 
leading to a higher intraterminal influx of Ca2+. Therefore recruitment of these 
long-lasting channels could account for a compensatory mechanism in order to 
sustain NMT and result in increased concentration of the divalent ion at NMJs. 
However this could also contribute to the typical Ca2+ toxicity in ALS. Since L-
type VGCCs are important in presynaptic autofacilitation of ACh release [133] 
and have an A2AR-mediated recruitment in high frequency stimuli [91], pre-
symptomatic SOD1G93A mice upregulation of A2AR could contribute to the 
neurodegenerative mechanisms occurring at transgenic NMJs. 
 Spontaneous events arise from intracellular Ca2+ store mobilization upon 
RyRs activation, and are independent of extracellular Ca2+ levels [102]. CGS 
21680 at tested concentrations (3, 5 and 10 nM) only increased the frequency 
of the spontaneous events (MEPPs and GMEPPs) highlighting the presynaptic 
action of A2AR [123].  
 It has been show that IgGs from sporadic ALS patients can lead to higher 
frequency of spontaneous events in mice phrenic nerve-hemidiaphragm 
preparations through Ca2+ influx from N-type VGCCs and PLC recruitment with 
RyR and IP3 receptors being needed to sustain this feature [101]. A2AR 
activation results in increased spontaneous release through direct stimulation of 
ryanodine sensitive stores, while in K+-evoked conditions A2AR signalization 
positively modulates L-type VGCC which may induce the opening of RyRs by 
increasing gating charge movements [102]. Pre-symptomatic terminals are 
more competent in handling activity-dependent Ca2+ load at moderate firing 
frequencies, but distinct mechanisms become apparent in maximal stimulation 
83 
 
resulting in higher peak Ca2+ amplitudes [63]. The different A2AR regulation of 
MEPP frequency in pre-symptomatic SOD1G93A fibers could be related with: 
(1) increased A2AR signaling leading to an uncontrolled resting intraterminal 
[Ca2+] which could underlie the noticed changes in spontaneous release; (2) a 
deficient regulation of Ca2+ intracellular stores mechanisms that control Ca2+ 
clearance and limit the duration of the EPP [63], resulting in higher MEPP 
frequency upon A2AR activation; or (3) abnormal RyR Ca2+-sensitization [134] 
resulting in A2AR promoted Ca2+-induced Ca2+-release from the ER explainable 
of observed results (see[135]) This mechanism could play a major role during 
high frequency bursts. But these hypotheses need further investigation. 
 In SOD1G93A muscle strength is lost and denervation starts before 
symptoms onset [41]. Muscle strength depends on the firing frequency and 
motor unit recruitment [136]. Pre-junctional changes in [Ca2+] homeostasis may 
induce adaptations to facilitate firing frequency, specifically during high-
frequency stimulation [128]. An increase in intraterminal [Ca2+] could be derived 
from A2AR recruitment of VGCCs via PKA [137]. This may lead to higher 
nicotinic autofacilitation via α3β2 nAChR or higher intracellular store 
mobilization of Ca2+ attributable to pre-symptomatic pro-inflamatory factors 
present in SOD1G93A mice such as IgGs [138]. 
 GMEPP frequency increase in pre-symptomatic mice is suggestive of 
enhanced synchronism in vesicle release, and highlights the role of A2AR in the 
facilitation of synchronous spontaneous release. GMEPP are also more present 
in pathological conditions, during reinervation processes and ageing [139-140] 
(but see[141]). Presynaptic terminal arrangement of ACh vesicles in 
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SOD1G93A may predispose to higher GMEPP frequency in the presence of 
CGS 21680 (5nM). Changes in resting intra-terminal [Ca2+] concentration by 
mechanisms of Ca2+ influx, pointed before, may also trigger an increase in 
basal [Ca2+] resulting in higher spontaneous synchronous release  [140]. 
5.3. A2A adenosine receptors modulation of acetylcholine release is lost 
in symptomatic SOD1G93A mice 
 Evoked activity (EPP amplitude and QC) in symptomatic mice is not 
changed by CGS 21680 (3, 5, 10 and 25nM) perfusion, contrasting with the 
effect of the A2AR agonist in WT mice. Symptomatic SOD1G93A display a 
reduced expression of A2AR in the spinal cord, a decrease that is mimicked in 
age-matched WT mice by chronic administration of caffeine (non-selective 
adenosine receptor antagonist) [104].  
 It is known that A2AR may decrease nicotinic autofaciltiation by favouring 
autodesensitisation of α3β2 nAChR at high-stimulated NMJs, perhaps to 
prevent ACh flooding and Ca2+ excitotoxicity [142]. With a high intraterminal 
[Ca2+] VGCC recruitment could be decreased, like in other neuromuscular 
diseases such as myasthenia gravis where an abnormal A2AR interaction with 
L-type VGCC renders rat NMJs susceptible to tetanic failure [143]. The C-
terminus of the L-type VGCC has a regulatory Ca2+ dependent inactivation and 
activation. This channel is also controlled by calmodulin, a Ca2+ binding 
messenger protein (see[144]). Calmodulin can interact with the A2AR structure 
producing conformational changes and shifts in signaling, a feature present in 
A2AR and dopamine D2 receptors heteromers [145]. Pre-symptomatic 
SOD1G93A Ca2+ transient hyperexcitability is lost when symptoms arise, and 
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Ca2+ overload at the MN terminal determines cell death due to deficient Ca2+ 
clearance [63]. In symptomatic SOD1G93A mice Ca2+ dysfunction may affect 
A2AR functionality resulting in cellular changes that impair the evoked 
excitatory adenosinergic action. 
 A picture of contrast can be observed between both WT and SOD1G93A 
mice at the different studied ages. In WT there was an increase in evoked 
activity in 12-14 wo mice when comparing with 4-6 wo animals, along with a 
shift in the concentration of the A2AR agonist concentration that can elicit the 
maximum effect in ACh facilitation (3-5nM in 4-6 wo WT and 10 nM in 12-14 
wo), however non-significant. SOD1G93A presented an opposite feature. WT 
mice may undergo synapse maturation while SOD1G93A compensatory 
mechanisms may lead to a typical ALS-hyperexcitability envolving an A2AR 
functional enhancement  at the NMJ. When symptoms arise A2AR modulation 
is lost in transgenic mice probability due to denervation processes, deficient 
signaling or as means to avoid Ca2+ excitotoxicity. Therefore A2AR functional 
downregulation could be a protective endstage mechanism to delay MN death.  
 In rat hemidiapragm, muscle paralysis by µ-conotoxin GIIIB decreased 
nerve evoked adenosine outflow around 90% [143]. In high-frequency 
stimulation a higher amount of adenosine may come from ATP breakdown 
which can then be uptaken by an adenosine sensitive transporter in rat skeletal 
muscle [146]. This may indicate that at our stimulus paradigm most of 
endogenous adenosine might come from the muscle fiber. Given the 
neurodegenerative events in ALS muscle, and since extracellular adenosine 
levels can be elevated in pathological conditions (see [93]), increased 
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extracellular adenosine levels might be present in symptomatic SOD1G93A 
mice resulting in an ablation of A2AR functionality. If adenosine is increased in 
the synaptic clef of transgenic animals, A2AR are not tonically activated since 
SCH 58261 (50nM) did not change EPP amplitude nor QC. Therefore perfusion 
of adenosine deaminase in phrenic nerve-hemidiaphragm preparations in the 
presence of the A2AR agonist could clarify this hypothesis. 
 NMJ alterations in old mice parallel with the observations in symptomatic 
SOD1G93A mice [147]. In ageing, a shift from fast towards slow twitch fibers is 
observed [148-149] involving purinergic modulation through adenine nucleotide 
release by the skeletal muscle [150]. Considering that early denervation occurs 
in ALS mice muscle with a fast to slow fiber transition, this may also contribute 
to changes in A2AR modulation. 
 Regarding spontaneous activity there was no change in MEPP frequency 
in symptomatic SOD1G93A rodents. One feature of ALS is the ER-stress that 
starts in the pre-symptomatic phase, and increases throughout disease 
progression. Mitochrondrial dysfunction, proteossome impairment and deficient 
cellular signaling are typical features of ER-stress (see [151]). Therefore A2AR 
action on intracellular Ca2+ stores can be lost in symptomatic SOD1G93A mice 
in contrast with age-matched controls. High levels of intra-terminal Ca2+ can 
lead to desensitization of intracellular Ca2+ release machinery such as RyR 
[134].The Ca2+ dysfunction in SOD1G93A animals could therefore impair the 
regulatory action of A2AR in the mobilization of internal Ca2+ stores. This could 
result in the observed unchanged MEPP and GMEPP frequency when CGS 
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21680 was added to the physiological solution in symptomatic SOD1G93A 
mice. 
 WT mice present an increase in MEPP frequency in 12-14 wo animals 
when compared to 4-6 wo mice in the presence of CGS 21680 (5nM). This 
could be a feature of NMJ maturation, like previously suggested when 
discussing the evoked activity. Symptomatic SOD1G93A NMT modulation of 
spontaneous activity is lost, highlighting neurodegenerative processes that 






6. Summary and Conclusions 
 We have put in evidence that pre-symptomatic SOD1G93A mice have a 
functional upregulation of A2AR in diaphragmatic NMJs, resulting in increased 
evoked quantal release when comparing to age-matched WT mice. 
Desynchronized (MEPPs) and synchronized (GMEPPs) spontaneous release 
frequency was also increased in SOD1G93A mice when A2AR were activated. 
This suggested the occurrence of changes in intraterminal [Ca2+] regulation of 
ACh release in this mouse model involving A2AR signaling before symptoms 
onset. 
 The A2AR pre-symptomatic functional enhancement is lost when 
symptoms arise. This might be attributable to the pathological mechanisms 
inherent to the disease or to an adaptive shift in order to avoid intraterminal 
Ca2+ overload that would predispose MNs to cell death and increased functional 
impairment. 
 Our work points out changes related with A2AR role in the control of ACh 
release in SOD1G93A NMJs, highlighting the role of these purinergic receptors 




7. Future developments 
 The crosstalk between A1R and A2AR receptors must be explored in this 
model (work in progress). This may unveil different control and interaction 
between these receptors suggestible of the changes observed in the A2AR 
study.  
 Experiments with adenosine deaminase, may help to unveil if 
endogenous adenosine is masking the CGS 21680 effect in symptomatic 
animals either by desensitization of A2AR, tonic activation of A1R resulting in 
decreased A2AR function or increased binding competition with the A2AR 
agonist. 
 Due to the role of VGCC in ALS, more specifically the L-type, 
experiments with nitrendipine could be conducted in the presence of CGS 
21680 to understand the role of A2AR in the recruitment of these channels. 
Blockers of P/Q-type and N-type VGCC could also be explored. The high affinity 
Ca2+ chelator BAPTA-AM could also be included in this role of experiments, 
together with the low affinity Ca2+ chelator EGTA-AM, in order to access the role 
and the tridimensional relationship between VGCC function and recruitment by 
A2AR in SOD1G93A. These two chelators could also be tested in the presence 
of ryanodine (RyR blocker) and tapsigargin (inhibitor of the sacro/endoplasmatic 
reticulum Ca2+ ATP-ase) to fully understand to role in intracellular store Ca2+ 
mobilization by A2AR in SOD1G93A mice. 
 It would also be interesting to explore if the A2AR changes in the NMJ of 
SOD1G93A are reverberated in the spinal cord and motor cortex, in order to 
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explore the pattern of adenosinergic dysfunction in ALS from the central 
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